

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Changing Conversations in Primary Care for Patients Living with Chronic Conditions: A Pilot and Feasibility Study of the ICAN Discussion Aid

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029105
Article Type:	Research
Date Submitted by the Author:	21-Jan-2019
Complete List of Authors:	Boehmer, Kasey R.; Mayo Clin, Dobler, Claudia; Mayo Clin, Knowledge and Evaluation Research Unit; 2. Evidence-Based Practice Center, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery Thota, Anjali; Mayo Clin, Knowledge and Evaluation Research Unit Branda, Megan; Mayo Clinic, Health Sciences Research Giblon, Rachel; Mayo Clin, 3. Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery Behnken, Emma; Mayo Clin, Knowledge and Evaluation Research Unit Organick, Paige; Mayo Clin, Knowledge and Evaluation Research Unit Allen, Summer; Mayo Clin, Knowledge and Evaluation Research Unit; Department of Family Medicine Shaw, Kevin; Mayo Clin, Knowledge and Evaluation Research Unit Montori, Victor; Mayo Clinic, Knowledge and Encounter Research Unit
Keywords:	patient-centered care, minimally disruptive medicine, healthcare communication, chronic disease, multimorbidity

SCHOLARONE™  
Manuscripts

## Changing Conversations in Primary Care for Patients Living with Chronic Conditions: A Pilot and Feasibility Study of the ICAN Discussion Aid

Kasey R. Boehmer, PhD, MPH<sub>1</sub> ([Boehmer.kasey@mayo.edu](mailto:Boehmer.kasey@mayo.edu))

Claudia C. Dobler, MD, PhD<sub>1,2</sub> ([Dobler.claudia@mayo.edu](mailto:Dobler.claudia@mayo.edu))

Anjali Thota, BA<sub>1</sub> ([Thota.anjali@mayo.edu](mailto:Thota.anjali@mayo.edu))

Megan Branda, MS<sub>3</sub> ([Branda.megan@mayo.edu](mailto:Branda.megan@mayo.edu))

Rachel Giblon, MS<sub>3</sub> ([Giblon.rachel@mayo.edu](mailto:Giblon.rachel@mayo.edu))

Emma Behnken, BA<sub>1</sub> ([Behnken.emma@mayo.edu](mailto:Behnken.emma@mayo.edu))

Paige Organick, BA<sub>1</sub> ([Organick.paige@mayo.edu](mailto:Organick.paige@mayo.edu))

Summer V. Allen, MD<sub>1,4</sub> ([Allen.summer@mayo.edu](mailto:Allen.summer@mayo.edu))

Kevin Shaw, BA<sub>1</sub> ([Shaw.kevin@mayo.edu](mailto:Shaw.kevin@mayo.edu))

Victor M. Montori, MD, MSc<sub>1</sub> ([Montori.victor@mayo.edu](mailto:Montori.victor@mayo.edu))

1. Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota, USA
2. Evidence-Based Practice Center, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA
3. Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA
4. Department of Family Medicine, Mayo Clinic, Rochester, Minnesota

### Corresponding Author:

Kasey R. Boehmer, PhD, MPH  
Mayo Clinic  
200 First Street SW  
Rochester, MN 55905

**Support:** Funded by an internal Mayo Clinic Award from the Robert & Arlene Kogod Center for Aging

**Prior Presentations:** International Shared Decision Making Conference, Lyon, France, 2017; International Conference on Communication in Healthcare, Baltimore, MD, USA, 2017; North American Primary Care Research Group Conference, Montreal, Canada, 2017

**Word Count:** 2,680; 2 Figures, 4 Tables, 1 Appendix

## Abstract

**Purpose:** To pilot test the impact of the ICAN Discussion Aid on clinical encounters.

**Methods:** A pre-post study involving 11 clinicians and 100 patients was conducted at two primary care clinics within a single health system in the Midwest. The study examined clinicians' perceptions about ICAN feasibility, patients' and clinicians' perceptions about encounter success, videographic differences in encounter topics, and medication adherence 6-months after an ICAN encounter.

**Results:** 40/40 control encounters and 45/60 ICAN encounters yielded usable data. Clinicians reported ICAN use was feasible. In ICAN encounters, patients discussed diet, being active, and taking medications more. Clinicians scored themselves poorer regarding visit success than their patients scored them; this effect was more pronounced in ICAN encounters. ICAN did not improve 6-month medication adherence or lengthen visits.

**Conclusion:** This pilot study suggests that using ICAN in primary care is feasible, efficient, and capable of modifying conversations. With lessons learned in this pilot, we are conducting a randomized trial of ICAN vs. usual care in diverse clinical settings.

**Abstract Word Count:** 167

**Keywords:** patient-centered care; minimally disruptive medicine; healthcare communication; chronic disease; multimorbidity

**Trial Registration:** NCT02390570; registered 2/19/2015

### Article Summary: Strengths and limitations of this study

- Small before-after pilot study limiting the ability to draw statistical inferences that would be possible in a larger trial with a randomized design.
- Not powered to assess clinical significance for patient-reported outcomes nor prescription adherence; lack of difference found is not indicative of one not existing
- Single healthcare system in the Midwest with a fairly homogenous patient population limiting generalizability
- Small size was a strength in allowing us to pursue video-recording of all encounters, allowing deeper exploration of ICAN's impact on conversations and additional training needs for future implementation and testing

## 1. Introduction

Estimates in 2013 indicated that 117 million, or approximately half of adults in the U.S. had one or more chronic conditions,<sup>1</sup> while 26% of adults in the U.S. had multiple chronic conditions (MCC).<sup>2</sup> Patients living with chronic conditions must cope with the burden of illness and additionally invest time and energy to comprehend, manage, and access professional healthcare – the work of being a patient. If this work is not carefully managed and monitored, patients may experience treatment burden.<sup>3,4</sup>

Treatment burden often goes unnoticed, as clinical practice guidelines focus on managing individual conditions, without explicit consideration of co-morbidities or the patient's values, preferences, and context.<sup>5</sup> If implemented in this way, the application of all guideline recommendations may overwhelm patients<sup>6-8</sup>. Similarly, clinical practice does not often acknowledge patients' potentially limited capacity to handle complexity of life and healthcare work, which leads to the prescription of treatment plans that require capacity of patients and their caregivers that they may not have.<sup>9,10</sup>

This situation not only impacts patients and families, but has also led to burnt-out clinicians.<sup>11</sup> Beyond medical complexity described above, clinicians also need to consider non-medical complexity, (e.g., difficulty affording medications, unstable housing, and problematic family dynamics), and the body of literature is growing to show that clinicians have difficulty with conversations where medical and non-medical complexity intersect.<sup>12-16</sup>

The ICAN Discussion Aid (**Figure 1**) was developed using a robust user-centered design process, previously used to develop decision aids,<sup>17 18</sup> to address these problems. To date, it remains untested.

### 1.2. Aim

We aimed to evaluate the feasibility of using the ICAN Discussion Aid in primary care and to estimate its impact on clinical care, including patient and clinician-perceived success of visits, length of visits, and topics of conversation.

## 2. Methods

To pilot test the ICAN Discussion Aid, we conducted a pre-test versus post-test intervention study.

### 2.1. Ethics

All study procedures were approved by the Mayo Clinic IRB (14-008621); patient and clinician participants consented for data collection procedures.

### 2.2. Participant Eligibility and Recruitment

Clinicians were recruited from two clinical sites in the Midwest and were eligible for participation if they regularly saw patients with chronic conditions. Clinicians were consented for participation either at a lunch-hour clinical practice meeting or immediately before their first eligible patient. Adult patients were eligible if they had one or more chronic conditions, no major barriers to consent (e.g. cognitive impairment), and were seeing a clinician who had agreed to participate. Patients were approached immediately before the encounter with their clinician.

### 2.3 Study Procedures

After both clinician and patient were enrolled in the study, a trained study coordinator set up a small video camera (i.e., FlipCam, GoPro) to record the clinic visit. Patients and clinicians could turn the video camera off at any time if they felt uncomfortable, and the video camera was always turned around or off during physical exams. Following the encounter, both patient and

1  
2  
3 clinician were given a survey to complete immediately or return in a postage-paid return  
4  
5 envelope. The study coordinator followed-up on surveys not returned within one week. The first  
6  
7 40 clinical encounters were usual care. After the first 40 encounters, clinicians were then trained  
8  
9 during a standing meeting or individually on how to use the ICAN Discussion Aid. The  
10  
11 remaining 60 clinical encounters were intended to be ICAN encounters.  
12  
13

#### 14 15 16 2.4. *Intervention: The ICAN Discussion Aid* 17

18  
19 The study coordinator provided instructions for the patient to complete the ICAN  
20  
21 Discussion Aid (**Figure 1**) before the clinician entered the room. When the clinician entered the  
22  
23 room, he or she would select one of three opening questions to elicit responses from the patient,  
24  
25 and would then explore the information that the patient provided in ICAN by asking “What  
26  
27 stands out to you on this sheet you filled?” Clinicians were instructed to discuss that issue alone  
28  
29 and connect it to the reason for the visit that day. Clinical conversation was expected to proceed  
30  
31 as usual with incorporation of the ICAN information.  
32  
33

#### 34 35 2.5. *Measures* 36

37  
38 Clinician degree, position, and gender were collected at baseline. Patient characteristics  
39  
40 of age, sex and marital status were abstracted from the medical record. To assess *perceived*  
41  
42 *success* of the encounter, we used the Consultation Care Measure (CCM), a valid and  
43  
44 discriminating tool to measure communication and partnership within a single encounter,  
45  
46 previously correlated with patient satisfaction, enablement, and reduced symptom burden.<sup>19</sup> The  
47  
48 measure asks patients to what extent they agree with statements about the doctor such as he/she  
49  
50 “was interested in what I thought the problem was.”<sup>19</sup> For clinician surveys, we used a modified  
51  
52 version of the patient CCM, adjusted to the clinician perspective, which was not previously  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 validated. For example, the patient might be asked the extent to which they felt the clinician  
4  
5 “was careful to explain the plan of treatment.” Whereas the clinician would be asked the extent  
6  
7 to which they agreed with the statement that they felt that they “were careful to explain the plan  
8  
9 of treatment.” To assess *feasibility* of ICAN use, we asked clinicians to report how easy or  
10  
11 difficult the aid was to use in their encounter on a 5-point scale, from very easy to very difficult.  
12  
13 If clinicians marked difficult or very difficult, they were prompted to write a brief description of  
14  
15 why. To assess *adherence*, patients pharmaceutical records were collected as a means to provide  
16  
17 estimates of baseline adherence amongst patients in this population, and of whether using ICAN  
18  
19 potentially effects adherence through the tailoring of patient care plans to their life context.  
20  
21 Given the hypothesis generating nature of the adherence data, the methods and results are  
22  
23 provided in **Appendix 1**.

## 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

### 2.6. Videographic Coding Scheme

To assess ICAN’s *impact on clinical conversation topics*, we created an a priori video coding scheme, in which we coded each instance where the following topics were brought up: family, friends, free time, faith, living situation, being active, rest, comfort, emotional life, senses, memory, eating well, taking medications, making appointments, getting to appointments, administrative treatment work (e.g., dealing with insurance/billing, communicating with pharmacies), prescribed behaviors (e.g. getting mammograms, exercising a certain number of minutes per week), and other treatment work (i.e, work that the patient was asked to do but that did not fit into these other categories). Life issues listed in the coding scheme were those shown on ICAN and previously illustrated as important components of patient capacity from earlier work.<sup>18,20</sup> Treatment burden issues listed in the coding scheme were derived from typical issues listed in the development of ICAN and a taxonomy of treatment burden.<sup>18,21</sup> We also coded for



opening questions typically used in ICAN, designed to elicit the existence of competing priorities that could potentially limit the capacity for self-care or treatment, sources of joy in patients' lives, and immediate concerns (medical and non-medical). To assess *impact on length of visit*, we compared lengths of video recording.

### 2.7. Analyses

All statistical analyses were conducted in SAS (SAS Institute Inc., Version 9.4, Cary, NC, USA) and Stata (StataCorp, Release 15, College Station, TX). Videographic coding was done using Noldus Observer XT (version 11, Leesburg, VA). Patient and clinical encounter characteristics were compared between ICAN and control encounters using a t-test for continuous variables and a chi-square test for categorical variables. To explore differences in patient and clinician perceived success of an encounter, we subtracted unadjusted clinician scores from unadjusted patient scores, and tested for changes in the perceived success gap between ICAN and control encounters using a Wilcoxon Rank-Sum test. To test for differences across issues discussed in videos where patients and clinicians used ICAN versus those recorded in control encounters, we used a negative binomial model accounting for clustering within clinicians.

### 2.8 Patient and Public Involvement

The Knowledge and Evaluation Research Unit Patient Advisory Group participated in the design of the ICAN Discussion Aid, ensuring its relevance to patients living with chronic conditions and its ease of use. They were not consulted for the research design of the pilot study.

## 3. Results

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Eleven clinicians were enrolled from two primary care clinics within the Midwest, United States starting in October 2015. Seven clinicians approached declined enrollment, without providing a reason. The clinicians were primarily female (N=7, 64%) and were primarily physicians, with one nurse practitioner and two physician assistants. Patient enrollment began October 2015 and ended February 2017. 100 patients consented to participate (ICAN n=60). Detailed enrollment information is depicted in **Figure 2**. Of the eleven clinicians participating, one had all control encounters and five had all ICAN encounters. Patient characteristics are depicted in **Table 1**. Encounter length did not significantly differ between ICAN and control encounters.

### 3.1. Clinician reported feasibility of ICAN

Clinicians found the tool feasible to use in the majority of encounters. 62% reported it very easy or easy, 32% reported it as neither easy nor difficult, and 5% reported it was difficult to use in that encounter. There were two encounters where it was reported as difficult by different clinicians. For one encounter the clinician stated, "Unfortunately, this made her appointment go over by about 30 minutes. It was good we discussed issues with the portal [*an online platform that allows patients to access their health information*] and her life and stressors but it wasn't a big concern (why it wasn't a reason for the appointment) but we spent a good deal of time on it." Upon further review of this video, it appears that the primary reason that the encounter lasted substantially longer than planned was a lack of fidelity to ICAN training. After the clinician asked the patient what stood out to her from ICAN, she continued to elicit information about each burden listed by the patient, rather than connect the patient's response to the remainder of the clinical visit. Addressing the two key issues the patient brought up, work

1  
2  
3 stress and being active, took approximately five and a half minutes in total. Following that, the  
4  
5 clinician spent an additional five and a half minutes reviewing the other items on the tool.  
6

7  
8 In the second encounter, the clinician stated, “I enjoy the learning and conversation  
9  
10 obtained from form [sic] but didn't have the extra time in schedule [sic] necessary to address  
11  
12 each issue - easily added another 15-20 minutes to appointment.” In this encounter, the patient  
13  
14 indicated that her emotional life was both a source of satisfaction and a burden. The clinician  
15  
16 enquired further and thus provided the patient with an opportunity to talk about her prolonged  
17  
18 grief after the loss of her spouse and her concerns about possible depression. In response the  
19  
20 clinician screened the patient for potential depression. Total time using the tool and discussing  
21  
22 that issue took four minutes of the total visit. The patient was scheduled for a 45 minute general  
23  
24 medical exam, and the total video recorded visit time was 26 minutes, which did not include the  
25  
26 physical exam at the end of the encounter.  
27  
28  
29  
30

### 31 32 *3.2. Survey Results* 33 34

35 We did not find any items with significant differences between patients in either cohort  
36  
37 for the consultation care measure (**Table 2**). When comparing patients and clinicians across the  
38  
39 consultation care measure, among the items that overlapped, clinicians tended to score  
40  
41 themselves poorer than patients. This was more prevalent when the ICAN tool was used (**Table**  
42  
43 **3**).  
44  
45  
46

### 47 48 *3.3. Videographic Results* 49 50

51 Issues discussed during clinical encounters did significantly differ between ICAN and  
52  
53 control encounters in multiple domains (**Table 4**). Specifically, discussions about being active,  
54  
55 diet, and taking medications were discussed significantly more frequently in ICAN encounters.  
56  
57  
58  
59  
60

1  
2  
3 Discussions about administrative treatment work, other treatment work, family, living  
4 arrangements, and comfort were discussed significantly less frequently in ICAN encounters. We  
5  
6 noticed that often topics about family were used as conversation fillers in control encounters,  
7  
8 whereas there may have been less room for this when patients were prompted to bring up issues  
9  
10 that mattered most to them.  
11  
12  
13

## 14 15 16 **4. Discussion and Conclusion** 17

### 18 19 *4.1. Summary of Findings* 20

21  
22 Within this pilot trial, clinicians found the ICAN Discussion Aid to be a tool they could  
23 feasibly adopt into everyday practice and which did not impact the length of the visit. Patients  
24 discussed diet, being active, and taking medications more often in ICAN encounters.  
25  
26

27 Additionally, clinicians elicited competing priorities using ICAN opening questions that were  
28 never elicited during the opening of control encounters. While clinicians rated the perceived  
29 success of their encounters poorer than their patients (CCM score), and the gap between patient  
30 and clinician perceived success was larger ICAN encounters, the difference was not significant.  
31  
32 No difference was seen for adherence to prescription medications.  
33  
34  
35  
36  
37  
38

### 39 40 41 *4.2. Limitations and Strengths* 42

43  
44 These findings cannot be interpreted without considering the limitations in this study  
45 design. First, this study was a small before-after pilot study which limits our ability to draw  
46 statistical inferences that would be possible in a larger trial with a randomized design. The study  
47 was not powered to assess clinical significance for patient-reported outcomes nor prescription  
48 adherence and a lack of difference found is not indicative of one not existing. Furthermore, the  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 study occurred within a single healthcare system in the Midwest with a fairly homogenous  
4  
5 patient population of mostly high or middle socioeconomic status, which limits the  
6  
7 generalizability of the specific changes in topics present in ICAN conversations versus usual care  
8  
9 conversations. However, the small size of the study allowed us to pursue video-recording of all  
10  
11 encounters, which allowed for deeper exploration of ICAN's impact on conversations and to  
12  
13 point to additional needs for future implementation and testing of ICAN in practice that would  
14  
15 have been more difficult in a larger multi-site study.  
16  
17  
18  
19

#### 20 *4.3. Practice Implications*

21  
22  
23 Feasibility of ICAN use is an important finding on its own, given previously reported  
24  
25 challenges by clinicians in providing patient-centered care and participating in shared decision  
26  
27 making for populations living with MCC.<sup>22</sup> Furthermore, the difference in the topics brought up  
28  
29 in ICAN encounters suggests that patients are indeed more likely to be able to voice their topics  
30  
31 of choice, in an area where poor communication has been a noted frustration amongst patients.<sup>23</sup>  
32  
33 Diet, being active, and taking medications are not surprising topics to be most important to  
34  
35 patients in this setting and population (suburban, Midwest, academic medical center). However,  
36  
37 these topics have been noted as important treatment burden factors for patients in other diverse  
38  
39 samples; patients noted that they were aware their clinicians wanted them to eat healthier or  
40  
41 exercise more frequently, but important barriers existed of which their clinicians were unaware.<sup>24</sup>  
42  
43 Furthermore, in a previous study of patient-clinician concordance, patients were more likely than  
44  
45 clinicians to rank being active as one of their top three health concerns.<sup>25</sup> Future research should  
46  
47 examine whether the topics discussed more often are different in other clinical settings (e.g. rural  
48  
49 and urban), with different populations (e.g. unsalaried clinicians, underserved patients), and what  
50  
51 clinicians can do in clinical encounters with this information.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Examining the two encounters noted as difficult for clinicians yielded important information about ICAN implementation challenges. The encounter where additional time was used to discuss all ICAN items suggests that additional training may be needed for clinicians to illustrate how to connect the initial question of “What stands out to you?” to the clinical reason for the appointment, and how to continue the use of the discussion aid at future encounters. In the encounter in which the patient was able to discuss potential concerns of depression, the clinician noted that this added an additional 15 – 20 minutes to the encounter, whereas the actual discussion took less than five minutes. The perceived duration may have felt longer than the actual duration because of the heavy nature of the topic discussed. Past research in primary care patients with multi-morbidity has shown that clinician comfort level with these types of difficult topics is low and that in practicing a traditional “additive-sequential model,” where each problem is treated independently and prioritized, these issues may never get acknowledged.<sup>15,26</sup> Therefore, the implementation of ICAN can provide an opportunity to train clinicians to address potentially difficult topics, manage their expectations of those discussions, and learn how to successfully have those conversations.

#### 4.4. Conclusion

In conclusion, we successfully pilot tested the ICAN Discussion Aid in primary care encounters. This study illustrated that ICAN was perceived as feasible to implement in normal clinical practice, did not impact visit length, and impacted the conversation topics discussed in encounters. While patients perceived improved visit success with ICAN use, clinicians perceived worsened visit success. Clinical encounters that were noted as difficult to use ICAN point to additional ICAN training needs in future implementation and study settings.

### *Authors' contributions*

KRB was responsible for study design, overall study execution, analysis, and the draft manuscript. CCD and AT conducted videographic analysis and provided critical revisions for the manuscript. MB and RG conducted statistical analysis, created tables, and drafted the statistical sections of the manuscript. EB was responsible for study coordination of the study and data collection procedures. PO assisted with data cleaning procedures, drafting of the manuscript, and critical revisions to the manuscript. SVA served as clinical champion for the study and provided critical revisions to the manuscript. KS provided revisions to the manuscript and data visualization. VMM assisted KRB with study design and oversight of the project.

### *Conflicts of Interests*

The authors of this manuscript have no conflicts of interests to report.

### *Funding Statement*

This research was supported in part by an internal award from the Mayo Clinic Robert and Arlene Kogod Center for Aging.

### *Included Figures*

Figure 1: ICAN Discussion Aid

Figure 2: Detailed Enrollment Information

## References

1. Centers for Disease Control. Chronic Diseases: The Leading Causes of Death and Disability in the United States. 2017; <https://www.cdc.gov/chronicdisease/overview/>. Accessed May 17, 2018.
2. Ward BW, Schiller JS. Prevalence of multiple chronic conditions among US adults: estimates from the National Health Interview Survey, 2010. *Prev Chronic Dis*. 2013;10:E65.
3. Eton DT, Ramalho de Oliveira D, Egginton JS, et al. Building a measurement framework of burden of treatment in complex patients with chronic conditions: a qualitative study. *Patient Relat Outcome Meas*. 2012;3:39-49.
4. Ridgeway JL. Factors that lessen the burden of treatment in complex patients with chronic conditions: A qualitative study. In:2013.
5. Wyatt KD, Stuart LM, Brito JP, et al. Out of context: clinical practice guidelines and patients with multiple chronic conditions: a systematic review. *Med Care*. 2014;52 Suppl 3:S92-S100.
6. Gallacher K, May CR, Montori VM, Mair FS. Understanding patients' experiences of treatment burden in chronic heart failure using normalization process theory. *Ann Fam Med*. 2011;9(3):235-243.
7. Gallacher K, Morrison D, Jani B, et al. Uncovering treatment burden as a key concept for stroke care: a systematic review of qualitative research. *PLoS Med*. 2013;10(6):e1001473.



- 1
- 2
- 3 8. Shippee ND, Shippee TP, Hess EP, Beebe TJ. An observational study of emergency
- 4 department utilization among enrollees of Minnesota Health Care Programs: financial
- 5 and non-financial barriers have different associations. *BMC Health Serv Res.* 2014;14:62.
- 6
- 7
- 8
- 9
- 10 9. May C, Montori VM, Mair FS. We need minimally disruptive medicine. *Bmj.*
- 11 2009;339:b2803.
- 12
- 13
- 14 10. May CR, Eton DT, Boehmer K, et al. Rethinking the patient: using Burden of Treatment
- 15 Theory to understand the changing dynamics of illness. *BMC Health Serv Res.*
- 16 2014;14:281.
- 17
- 18
- 19
- 20
- 21 11. Bodenheimer T, Chen E, Bennett HD. Confronting the growing burden of chronic
- 22 disease: can the U.S. health care workforce do the job? *Health Aff (Millwood).*
- 23 2009;28(1):64-74.
- 24
- 25
- 26
- 27
- 28 12. Bayliss EA, Ellis JL, Steiner JF. Seniors' self-reported multimorbidity captured
- 29 biopsychosocial factors not incorporated into two other data-based morbidity measures. *J*
- 30 *Clin Epidemiol.* 2009;62(5):550-557.e551.
- 31
- 32
- 33 13. Cottrell E, Yardley S. Lived experiences of multimorbidity: An interpretative meta-
- 34 synthesis of patients', general practitioners' and trainees' perceptions. *Chronic Illn.*
- 35 2015;11(4):279-303.
- 36
- 37
- 38 14. Loeb DF, Binswanger IA, Candrian C, Bayliss EA. Primary care physician insights into a
- 39 typology of the complex patient in primary care. *Ann Fam Med.* 2015;13(5):451-455.
- 40
- 41
- 42 15. O'Brien R, Wyke S, Guthrie B, Watt G, Mercer S. An 'endless struggle': a qualitative
- 43 study of general practitioners' and practice nurses' experiences of managing
- 44 multimorbidity in socio-economically deprived areas of Scotland. *Chronic Illn.*
- 45 2011;7(1):45-59.
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

16. Safford MM. The Complexity of Complex Patients. *J Gen Intern Med*. 2015;30(12):1724-1725.
17. Breslin M, Mullan RJ, Montori VM. The design of a decision aid about diabetes medications for use during the consultation with patients with type 2 diabetes. *Patient Educ Couns*. 2008;73(3):465-472.
18. Boehmer KR, Hargraves IG, Allen SV, Matthews MR, Maher C, Montori VM. Meaningful Conversations in Living with and Treating Chronic Conditions: Development of the ICAN Discussion Aid. *BMC Health Serv Res*. 2016.
19. Little P, Everitt H, Williamson I, et al. Observational study of effect of patient centredness and positive approach on outcomes of general practice consultations. *Bmj*. 2001;323(7318):908-911.
20. Boehmer KR, Gionfriddo MR, Rodriguez-Gutierrez R, et al. Patient capacity and constraints in the experience of chronic disease: a qualitative systematic review and thematic synthesis. *BMC family practice*. 2016;17(1):127.
21. Tran VT, Barnes C, Montori VM, Falissard B, Ravaud P. Taxonomy of the burden of treatment: a multi-country web-based qualitative study of patients with chronic conditions. *BMC Med*. 2015;13:115.
22. Academy of Medical Sciences. Multimorbidity: A priority for global health research. 2018; <https://acmedsci.ac.uk/policy/policy-projects/multimorbidity>. Accessed June 6, 2018.
23. Gill A, Kuluski K, Jaakkimainen L, Naganathan G, Upshur R, Wodchis WP. "Where do we go from here?" Health system frustrations expressed by patients with multimorbidity, their caregivers and family physicians. *Healthc Policy*. 2014;9(4):73-89.

- 1  
2  
3 24. Eton DT, Ridgeway JL, Egginton JS, et al. Finalizing a measurement framework for the  
4 burden of treatment in complex patients with chronic conditions. *Patient Relat Outcome*  
5 *Meas.* 2015;6:117-126.  
6  
7  
8  
9  
10 25. Zulman DM, Kerr EA, Hofer TP, Heisler M, Zikmund-Fisher BJ. Patient-provider  
11 concordance in the prioritization of health conditions among hypertensive diabetes  
12 patients. *J Gen Intern Med.* 2010;25(5):408-414.  
13  
14  
15  
16  
17 26. Bower P, Macdonald W, Harkness E, et al. Multimorbidity, service organization and  
18 clinical decision making in primary care: a qualitative study. *Fam Pract.* 2011;28(5):579-  
19 587.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	ICAN (N=57*)	Pre-Intervention (N=40)	Total (N=97)	p value
<b>Sex</b>				0.09
Female	40 (70.2%)	34 (85.0%)	74 (76.3%)	
<b>Age: Mean (SD)</b>	62.7 (12.0)	66.8 (15.0)	64.4 (13.4)	0.05
<b>Marital status</b>				0.37
Divorced	11 (19.3%)	3 (7.5%)	14 (14.4%)	
Married	36 (63.2%)	27 (67.5%)	63 (64.9%)	
Single	5 (8.8%)	4 (10.0%)	9 (9.3%)	
Widowed	5 (8.8%)	6 (15.0%)	11 (11.3%)	
<b>Length of encounter (minutes): Mean (SD)</b>	31.6 (13.4)	34.5 (11.7)	32.9 (12.7)	0.25
Median (Q1, Q3)	31.3 (19, 41)	34.3 (25, 44)	33.6 (22, 42)	

<sup>^</sup>All enrolled patients.

\*3 patients in intervention missing data on characteristics.

**Table 2: CCM Patient Scores**

	ICAN (N=42)	Pre-Intervention (N=39)	Total (N=81)
<b>Overall score</b>			
Mean (SD)	29.7 (11.0)	28.6 (12.4)	29.2(11.6)
Median (Range)	25 (21, 62)	23 (21, 74)	24 (21, 74)
Adjusted mean* (95% CI)	31.5 (24.6, 38.5)	34.6 (29.3, 42.9)	

\*Adjusted by clinician clustering; lower scores = better

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2019-029105 on 3 September 2019. Downloaded from <http://bmjopen.bmj.com/> on April 23, 2024 by guest. Protected by copyright.

**Table 3: Clinician – Patient Difference in individual CCM scores**

	ICAN (N=38)*	Pre-Intervention (n=39)*	P-Value
1/E: Careful to explain	0.87 (0.52, 1.22)	0.64 (0.32, 0.96)	0.33
2/F: Was sympathetic	0.97 (0.57, 1.37)	0.54 (0.19, 0.89)	0.09
3/H: discussed & agreed together what problem was	0.97 (0.61, 1.33)	0.51 (0.19, 0.84)	0.047
4/K: discussed & agreed on plan of treatment	0.84 (0.51, 1.17)	0.59 (0.25, 0.93)	0.26
5/M: understood emotional needs	0.97 (0.43, 1.52)	0.77 (0.39, 1.15)	0.31
6/N: confident knows patient history	0.66 (0.23, 1.09)	0.77 (0.40, 1.14)	0.91
7/T: interested in effect of problem on family and personal life	0.68 (0.22, 1.15)	0.64 (0.27, 1.02)	0.73
8/U: interested in effect of problem on everyday life	0.82 (0.35, 1.29)	0.74 (0.39, 1.10)	0.60

Mean (95% CI), p-value Wilcoxon rank sum test


\* Difference in scores calculated as clinician score minus patient score for encounter. Higher scores correspond to lower performance on the CCM tool.

	Behaviors *	All Encounters (n=84/ICAN= 45)		Patients (n=84)		Clinicians (n=84)	
		IRR (95% CI)	P value	IRR (95% CI)	P value	IRR (95% CI)	P value
<b>More likely with ICAN</b>	<b>Being active</b>	<b>1.52 (1.09, 2.11)</b>	<b>0.01</b>	<b>1.58 (1.12, 2.22)</b>	<b>0.008</b>	1.45 (0.95, 2.21)	0.09
	<b>Taking medications</b>	1.22 (0.99, 1.51)	0.06	<b>1.42 (1.20, 1.67)</b>	<b>&lt;.0001</b>	1.12 (0.85, 1.46)	0.42
	<b>Diet</b>	<b>2.02 (1.22, 3.32)</b>	<b>0.005</b>	<b>2.32 (1.39, 3.88)</b>	<b>0.001</b>	1.61 (0.93, 2.79)	0.09
	<b>Competing priorities</b>	<b>14.46 (4.00, 52.24)</b>	<b>&lt;.0001</b>	---**	---	<b>10.91 (3.63, 32.73)</b>	<b>&lt;.0001</b>
<b>Less Likely with ICAN</b>	<b>Other admin</b>	<b>0.56 (0.39, 0.82)</b>	<b>0.002</b>	0.74 (0.48, 1.13)	0.16	<b>0.47 (0.33, 0.69)</b>	<b>&lt;.0001</b>
	<b>Family</b>	<b>0.57 (0.36, 0.90)</b>	<b>0.02</b>	0.66 (0.42, 1.03)	0.05	<b>0.46 (0.28, 0.75)</b>	<b>0.002</b>
	<b>Faith</b>	<b>0.59 (0.42, 0.82)</b>	<b>0.002</b>	0.78 (0.44, 1.39)	0.41	0.36 (0.12, 1.05)	0.06
	<b>Senses</b>	<b>0.55 (0.30, 1.00)</b>	<b>0.05</b>	0.65 (0.35, 1.22)	0.18	<b>0.44 (0.23, 0.87)</b>	<b>0.02</b>
<b>No Difference with ICAN</b>	Other treatment work	0.90 (0.65, 1.24)	0.52	1.07 (0.71, 1.63)	0.74	0.77 (0.59, 1.01)	0.06
	Immediate concerns	1.11 (0.69, 1.76)	0.68	1.62 (0.86, 3.06)	0.14	0.90 (0.60, 1.37)	0.64
	Joy	---**	---	---**	---	---**	---
	Where I live	0.82 (0.50, 1.35)	0.44	1.09 (0.66, 1.80)	0.75	0.58 (0.32, 1.04)	0.07
	Comfort	0.76 (0.50, 1.16)	0.20	0.90 (0.62, 1.33)	0.61	0.63 (0.39, 1.01)	0.05
	Free time	1.08 (0.54, 2.16)	0.82	1.20 (0.60, 2.40)	0.61	0.96 (0.45, 2.04)	0.92
	Making appointments	0.76 (0.50, 1.16)	0.21	0.77 (0.49, 1.23)	0.27	0.75 (0.49, 1.15)	0.18
	Prescribed behaviors	0.84 (0.45, 1.58)	0.59	0.96 (0.57, 1.64)	0.89	0.80 (0.40, 1.61)	0.53
	Friends	0.75 (0.33, 1.66)	0.47	0.65 (0.30, 1.40)	0.27	1.41 (0.52, 3.75)	0.49
	Getting to appointments	1.24 (0.74, 2.08)	0.41	1.34 (0.76, 2.36)	0.32	1.09 (0.60, 2.00)	0.78
	Work	0.85 (0.60, 1.220)	0.39	1.05 (0.75, 1.47)	0.80	0.62 (0.38, 1.02)	0.06
	Rest	0.89 (0.52, 1.54)	0.68	0.92 (0.52, 1.59)	0.75	0.87 (0.46, 1.64)	0.67
	Emotional life	1.23 (0.54, 2.80)	0.63	1.56 (0.64, 3.83)	0.33	1.03 (0.41, 2.59)	0.95
	Volunteer	0.85 (0.30, 2.38)	0.76	0.57 (0.16, 2.04)	0.39	---**	---
	Personal meaning	2.39 (0.18, 32.56)	0.51	2.39 (0.18, 31.56)	0.51	---**	---
School	---**	---	---**	---	---**	---	
Memory	1.98 (0.70, 5.63)	0.20	2.41 (0.71, 8.25)	0.1596	0.80 (0.30, 2.13)	0.65	

IRR = Incidence Rate Ratio; >1 means more occurrences in ICAN encounters, <1 fewer occurrences in ICAN encounters

\*Adjusted for gender, age at enrollment, length of encounter and clustering around shared clinicians

\*\* Insufficient data for analysis



- What are you doing when you're not sitting here with me?
- Where do you find the most joy in your life?
- What's on your mind today?

These questions can help shift discussion towards the broader life of your patient. Use as many of them as you wish.

Are these areas of your life a source of satisfaction, burden, or both?

	Satisfaction	Burden
My family and friends	<input type="checkbox"/>	<input type="checkbox"/>
My work	<input type="checkbox"/>	<input type="checkbox"/>
Free time, relaxation, fun	<input type="checkbox"/>	<input type="checkbox"/>
Faith or personal meaning	<input type="checkbox"/>	<input type="checkbox"/>
Where I live	<input type="checkbox"/>	<input type="checkbox"/>
Getting out and transportation	<input type="checkbox"/>	<input type="checkbox"/>
Being active	<input type="checkbox"/>	<input type="checkbox"/>
My rest and comfort	<input type="checkbox"/>	<input type="checkbox"/>
My emotional life	<input type="checkbox"/>	<input type="checkbox"/>
My senses and memory	<input type="checkbox"/>	<input type="checkbox"/>
Eating well	<input type="checkbox"/>	<input type="checkbox"/>

What are the things that your doctors or clinic have asked you to do to care for your health?

Do you feel that they are a help, a burden, or both?

	Help	Burden
<i>example: come in for appointments</i>	<input type="checkbox"/>	<input type="checkbox"/>
<i>example: take aspirin</i>	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>

Figure 1: ICAN Discussion Aid  
419x215mm (300 x 300 DPI)






Figure 2: Detailed Enrollment Information

215x279mm (300 x 300 DPI)

## Appendix 1: Pharmaceutical prescription methods and results

*Measure*

Patients' prescriptions that had been filled were obtained from their pharmacies directly. We collected information on patients' filled prescriptions six months prior to enrollment to six months post-enrollment. Adherence to treatment was assessed for the six months post-enrollment by calculating the percentage of days out of the 180 day period for which a patient had a filled prescription.[23] Medications to treat chronic conditions were considered for inclusion in analysis.

<b>Appendix Table 1: Included Medications</b>	
<b>Medication Class</b>	<b>Medication Name</b>
<b>ACE inhibitor</b>	<b>Enalapril Maleate</b>
	<b>Lisinopril</b>
	<b>Ramipril</b>
<b>Alpha blocker</b>	<b>Tamsulosin</b>
	<b>Tamsulosin HCL</b>
<b>Alpha1 adrenergic blocker</b>	<b>Doxazosin Mesylate</b>
<b>Alpha2 delta ligand</b>	<b>Lyrica</b>
<b>Aminoketone antidepressant</b>	<b>Bupropion</b>
	<b>Bupropion HCL</b>
	<b>Bupropion HCL ER</b>
	<b>Bupropion XL</b>
	<b>SR Bupropion</b>
<b>Angiotensin receptor blocker (ARB)</b>	<b>Candesartan</b>
	<b>Lorsartan Potassium</b>
	<b>Losartan</b>
	<b>Losartan -HCTZ</b>
	<b>Losartan HCTZ</b>
	<b>Losartan Potassium</b>
	<b>Losartan-HCTZ</b>
	<b>Valsartan</b>
<b>Antiandrogen</b>	<b>Bicalutamide</b>
<b>Antiarrhythmic drug</b>	<b>Amiodarone</b>
	<b>Flecainide Acetate</b>

<b>Appendix Table 1: Included Medications</b>	
<b>Medication Class</b>	<b>Medication Name</b>
<b>Anticoagulant</b>	<b>Enoxaparin Sodium</b>
	<b>Jantoven</b>
	<b>Warfarin Sodium</b>
	<b>Xarelto</b>
<b>Anticonvulsant</b>	<b>Carbamazepine</b>
	<b>Carbamazepine ER</b>
	<b>Gabapentin</b>
	<b>Lamotrigine</b>
	<b>Topiramate</b>
	<b>Zonisamide</b>
<b>Anxiolytic antianxiety agent</b>	<b>Buspirone</b>
<b>Atypical antipsychotic</b>	<b>Latuda</b>
	<b>Quetiapine</b>
	<b>Quetiapine Fumarate</b>
<b>Beta blocker</b>	<b>Atendlol Chlorthalidone</b>
	<b>Atenolol</b>
	<b>Bisoprolol</b>
	<b>Carvedilol</b>
	<b>ER Metoprolol</b>
	<b>Metoprolol ER</b>
	<b>Metoprolol ER Succinate</b>
	<b>Metoprolol SUCC ER</b>
	<b>Metoprolol Tart</b>
	<b>Metoprolol Tartrate</b>
	<b>Metoprololhydrochloroth</b>
<b>Timolol Maleate</b>	
<b>Biguanide</b>	<b>Metforman</b>
	<b>Metformin</b>
	<b>Metformin ER</b>
	<b>Metformin HCL</b>

<b>Appendix Table 1: Included Medications</b>	
<b>Medication Class</b>	<b>Medication Name</b>
	<b>Metformin HCL ER</b>
	metformin
<b>Bisphosphonate</b>	<b>Alendronate</b>
	<b>Alendronate Sodium</b>
<b>Calcium channel blocker</b>	<b>Amlodipine</b>
	<b>Amlodipine Besylate</b>
	<b>Diltiazem HCL ER</b>
	<b>Nifedipine</b>
	<b>Verapamil HCR ER</b>
<b>Central alpha agonist</b>	<b>Clonidine HCL</b>
<b>Central muscle relaxant</b>	<b>Methocarbamol</b>
<b>Class 1b antiarrhythmic drug</b>	<b>Lidocaine</b>
<b>DDP4 inhibitor + biguanide</b>	<b>Janumet XR</b>
<b>Dibenzazepine</b>	<b>Tegretol XR</b>
<b>Digitalis glycoside</b>	<b>Digoxin</b>
<b>Disease modifying antirheumatic drug (DMARD)</b>	<b>Hydroxychloroquine Sulfate</b>
<b>Diuretic</b>	<b>Hydrochlorothiazide</b>
	<b>Hydrochlorothiazide</b>
	<b>Metolazone</b>
<b>Fibric acid</b>	<b>Fenofibrate</b>
	<b>Fenofibrate Micronized</b>
<b>Janus kinase (JAK) inhibitors</b>	<b>Xeljanz</b>
<b>Leukotriene receptor antagonists</b>	<b>Montelukast Sodium</b>
<b>Loop diuretic</b>	<b>Furobemide</b>
	<b>Furosemide</b>
	<b>Torsemide</b>
<b>Nitrate</b>	<b>Isosorb Mono ER</b>
	<b>Isosorbide MN ER</b>
<b>Nonergoline dopamine agonist</b>	<b>Pramipexole</b>
<b>Oral diuretic</b>	<b>Triamterene-HCTZ</b>

<b>Appendix Table 1: Included Medications</b>	
<b>Medication Class</b>	<b>Medication Name</b>
<b>P2Y12 inhibitor</b>	<b>Clopidogrel</b>
	<b>Clopidogrel Bisulfate</b>
<b>Phenylpiperazine antidepressant</b>	<b>Nefazodone HCL</b>
<b>Phosphodiesterase 4 (PDE4) inhibitors</b>	<b>Otezla</b>
<b>Potassium sparing diuretic</b>	<b>Spirolactone</b>
<b>SNRI</b>	<b>Desvenlafaxine ER</b>
	<b>Duloxetine DR</b>
	<b>Duloxetine HCL</b>
	<b>Duloxetine Hcl</b>
	<b>ER Venlafaxine</b>
	<b>Escitalopram Oxalate</b>
	<b>Venlafaxine XR</b>
	<b>Venlafaxin XR</b>
	<b>Venlafaxine ER</b>
	<b>Venlafaxine HCL ER</b>
<b>SSRI</b>	<b>Citalopram</b>
	<b>Citalpram</b>
	<b>Fluoxetine</b>
	<b>Fluoxetine HCL</b>
	<b>Paroxetine</b>
	<b>Paroxetine HCL</b>
	<b>Sertraline</b>
	<b>Sertraline HCL</b>
<b>Selective estrogen receptor modulator (SERM)</b>	<b>Raloxifene HCL</b>
	<b>Tamoxifen</b>
<b>Statin</b>	<b>Atorvastatin</b>
	<b>Atorvastatin Calcium</b>
	<b>Locastatin</b>
	<b>Lovastatin</b>

<b>Appendix Table 1: Included Medications</b>	
<b>Medication Class</b>	<b>Medication Name</b>
	<b>Pravastatin Sodium</b>
	<b>Rosuvastatin Calcium</b>
	<b>Simvastatin</b>
	<b>Vytorin</b>
<b>Sulfonylurea</b>	<b>Climepiride</b>
	<b>Glimepiride</b>
	<b>Glipizide</b>
	<b>Glipizide ER</b>
	<b>Glipizide XL</b>
<b>Tetracyclic antidepressant</b>	<b>Mirtazapine</b>
<b>Thiazide diuretic</b>	<b>Chlorthalidone</b>
<b>Thyroxine; T4 (synthetic)</b>	<b>Levothroxine</b>
	<b>Levothyroxine</b>
	<b>Levothyroxine SOD</b>
	<b>Synthroid</b>
<b>Triazolopyridine antidepressant</b>	<b>Trazodone HCL</b>
<b>Tricyclic antidepressant</b>	<b>Amitriptyline HCL</b>
	<b>Cyclobenzaprine HCL</b>
	<b>Cyclovenzaprine HCL</b>
	<b>Cyclovenzaprine HCL</b>
	<b>Nortriptyline</b>
	<b>Nortriptyline</b>
	<b>Nortriptyline HCL</b>
<b>Triiodothyronine</b>	<b>Liothyronine Sodium</b>
<b>Valeric acid</b>	<b>Gemfibrozil</b>
<b>Missing</b>	<b>Missing</b>
<b>Other / Unknown</b>	<b>Amsulosin</b>
	<b>Isometh-apap-dichlor-</b>
	<b>Metromin HCL</b>
	<b>Oxycodone 5MG IR Tabs</b>

### Statistical Analysis

Adherence to medications was assessed by medication class (i.e. if patient had multiple medications within a class, average adherence was calculated). Adherence was modeled using a hierarchical generalized linear model where the outcome was a patients' medication class adherence six months post enrollment. The model was clustered by patient, as patients could have multiple classes of medication, and adjusted by their adherence to the medication class in the six months prior to enrollment and intervention arm. Patients who did not have the medication class in the prior period were set to zero for baseline and a missing indicator was assessed in the model to address this. Patients with missing pharmacy data (e.g. their pharmacy

### Adherence Results

Similar rates of medication counts, medication classes and adherence were seen between groups in the six months prior to the encounter of interest (76% of days covered in patients in the ICAN group vs. 71% control) was unreachable for data request) were not included in the analysis.

<b>Appendix Table 2: Analysis of percent of days covered of medication classes by intervention.</b>			
	ICAN (N=53)	Pre- Intervention (N=27)	p value
<b>Count of medications prior to encounter</b>			0.57
Mean (SD)	3.6 (2.6)	4.2 (3.3)	
Median (IQR)	3 (2, 5)	4 (2, 5)	
<b>Count of medication classes prior to encounter</b>			0.54
Mean (SD)	3.4 (2.3)	3.9 (2.9)	
Median	3 (1, 5)	4 (2, 5)	
<b>Adherence (PDC) prior to encounter</b>			0.94
Mean (95% CI)	55% (50, 60)	54% (50, 60)	
<b>Count of medications post encounter</b>			0.37
Mean (SD)	3.8 (2.5)	4.1 (2.0)	
Median	3 (2, 5)	4 (3, 5)	
<b>Count of medication classes post encounter</b>			0.36
Mean (SD)	3.6 (2.3)	3.9 (1.8)	
Median	3 (2, 5)	4 (3, 5)	

<b>Appendix Table 2: Analysis of percent of days covered of medication classes by intervention.</b>			
	ICAN (N=53)	Pre- Intervention (N=27)	p value
<b>Adherence (PDC) post encounter</b>			0.56
Mean (95% CI)	75% (70, 80)	71% (60, 80)	
<b>Adjusted adherence (PDC) post encounter<sup>^</sup></b>			0.43
Mean (95% CI)	76% (70, 80)	72% (60, 80)	

Acronym: PDC Percent of Days Covered

\* Prior and post encounter periods are each 6 months long.

<sup>^</sup> ANCOVA with random effect of clinician and adjusted by prior 6 months adherence and intervention.



# BMJ Open

## Changing Conversations in Primary Care for Patients Living with Chronic Conditions: A Pilot and Feasibility Study of the ICAN Discussion Aid

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029105.R1
Article Type:	Research
Date Submitted by the Author:	28-May-2019
Complete List of Authors:	Boehmer, Kasey R.; Mayo Clin, Dobler, Claudia; Mayo Clin, Knowledge and Evaluation Research Unit; 2. Evidence-Based Practice Center, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery Thota, Anjali; Mayo Clin, Knowledge and Evaluation Research Unit Branda, Megan; Mayo Clinic, Health Sciences Research Giblon, Rachel; Mayo Clin, 3. Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery Behnken, Emma; Mayo Clin, Knowledge and Evaluation Research Unit Organick, Paige; Mayo Clin, Knowledge and Evaluation Research Unit Allen, Summer; Mayo Clin, Knowledge and Evaluation Research Unit; Department of Family Medicine Shaw, Kevin; Mayo Clin, Knowledge and Evaluation Research Unit Montori, Victor; Mayo Clinic, Knowledge and Encounter Research Unit
<b>Primary Subject Heading</b>:	Patient-centred medicine
Secondary Subject Heading:	Communication
Keywords:	patient-centered care, minimally disruptive medicine, healthcare communication, chronic disease, multimorbidity

SCHOLARONE™  
Manuscripts

## Changing Conversations in Primary Care for Patients Living with Chronic Conditions: A Pilot and Feasibility Study of the ICAN Discussion Aid

Kasey R. Boehmer, PhD, MPH<sub>1</sub> ([Boehmer.kasey@mayo.edu](mailto:Boehmer.kasey@mayo.edu))

Claudia C. Dobler, MD, PhD<sub>1,2</sub> ([Dobler.claudia@mayo.edu](mailto:Dobler.claudia@mayo.edu))

Anjali Thota, BA<sub>1</sub> ([Thota.anjali@mayo.edu](mailto:Thota.anjali@mayo.edu))

Megan Branda, MS<sub>3</sub> ([Branda.megan@mayo.edu](mailto:Branda.megan@mayo.edu))

Rachel Giblon, MS<sub>3</sub> ([Giblon.rachel@mayo.edu](mailto:Giblon.rachel@mayo.edu))

Emma Behnken, BA<sub>1</sub> ([Behnken.emma@mayo.edu](mailto:Behnken.emma@mayo.edu))

Paige Organick, BA<sub>1</sub> ([Organick.paige@mayo.edu](mailto:Organick.paige@mayo.edu))

Summer V. Allen, MD<sub>1,4</sub> ([Allen.summer@mayo.edu](mailto:Allen.summer@mayo.edu))

Kevin Shaw, BA<sub>1</sub> ([Shaw.kevin@mayo.edu](mailto:Shaw.kevin@mayo.edu))

Victor M. Montori, MD, MSc<sub>1</sub> ([Montori.victor@mayo.edu](mailto:Montori.victor@mayo.edu))

1. Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota, USA
2. Evidence-Based Practice Center, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA
3. Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA
4. Department of Family Medicine, Mayo Clinic, Rochester, Minnesota

### Corresponding Author:

Kasey R. Boehmer, PhD, MPH  
Mayo Clinic  
200 First Street SW  
Rochester, MN 55905

**Support:** Funded by an internal Mayo Clinic Award from the Robert & Arlene Kogod Center for Aging

**Prior Presentations:** International Shared Decision Making Conference, Lyon, France, 2017; International Conference on Communication in Healthcare, Baltimore, MD, USA, 2017; North American Primary Care Research Group Conference, Montreal, Canada, 2017

**Word Count:** 2,680; 2 Figures, 4 Tables, 1 Appendix

## Abstract

**Purpose:** To pilot test the impact of the ICAN Discussion Aid on clinical encounters.

**Methods:** A pre-post study involving 11 clinicians and 100 patients was conducted at two primary care clinics within a single health system in the Midwest. The study examined clinicians' perceptions about ICAN feasibility, patients' and clinicians' perceptions about encounter success, videographic differences in encounter topics, and medication adherence 6-months after an ICAN encounter.

**Results:** 40/40 control encounters and 45/60 ICAN encounters yielded usable data. Clinicians reported ICAN use was feasible. In ICAN encounters, patients discussed diet, being active, and taking medications more. Clinicians scored themselves poorer regarding visit success than their patients scored them; this effect was more pronounced in ICAN encounters. ICAN did not improve 6-month medication adherence or lengthen visits.

**Conclusion:** This pilot study suggests that using ICAN in primary care is feasible, efficient, and capable of modifying conversations. With lessons learned in this pilot, we are conducting a randomized trial of ICAN vs. usual care in diverse clinical settings.

**Abstract Word Count:** 167

**Keywords:** patient-centered care; minimally disruptive medicine; healthcare communication; chronic disease; multimorbidity

**Trial Registration:** NCT02390570; registered 2/19/2015

### Article Summary: Strengths and limitations of this study

- Small before-after pilot study limiting the ability to draw statistical inferences that would be possible in a larger trial with a randomized design.
- Not powered to assess clinical significance for patient-reported outcomes nor prescription adherence; lack of difference found is not indicative of one not existing
- Single healthcare system in the Midwest with a fairly homogenous patient population limiting generalizability
- Small size was a strength in allowing us to pursue video-recording of all encounters, allowing deeper exploration of ICAN's impact on conversations and additional training needs for future implementation and testing

## 1. Introduction

Estimates in 2013 indicated that 117 million, or approximately half of adults in the U.S. had one or more chronic conditions,<sup>1</sup> while 26% of adults in the U.S. had multiple chronic conditions (MCC).<sup>2</sup> Patients living with chronic conditions must cope with the burden of illness and additionally invest time and energy to comprehend, manage, and access professional healthcare – the work of being a patient. If this work is not carefully managed and monitored, patients may experience treatment burden.<sup>3,4</sup>

Treatment burden often goes unnoticed, as clinical practice guidelines focus on managing individual conditions, without explicit consideration of co-morbidities or the patient's values, preferences, and context.<sup>5</sup> If implemented in this way, the application of all guideline recommendations may overwhelm patients<sup>6-8</sup>. Similarly, clinical practice does not often acknowledge patients' potentially limited capacity to handle complexity of life and healthcare work, which leads to the prescription of treatment plans that require capacity of patients and their caregivers that they may not have.<sup>9,10</sup>

This situation not only impacts patients and families, but has also led to burnt-out clinicians.<sup>11</sup> Beyond medical complexity described above, clinicians also need to consider non-medical complexity, (e.g., difficulty affording medications, unstable housing, and problematic family dynamics), and the body of literature is growing to show that clinicians have difficulty with conversations where medical and non-medical complexity intersect.<sup>12-16</sup>

The ICAN Discussion Aid (**Figure 1**) was developed to address these problems, with the aim of enabling the discussion of patient workload, capacity, and treatment burden within the time constraints of busy primary care visits.<sup>17</sup> The process to develop ICAN is described in full elsewhere.<sup>17</sup> Briefly, it was developed using a robust, iterative user-centered design process,

1  
2  
3 previously used to develop decision aids<sup>18</sup> and was grounded in the Cumulative Complexity  
4  
5 Model, which states that patients living with chronic illness must enact both patient and life work  
6  
7 with limited capacity.<sup>19</sup> When workload exceeds patient capacity, it affects patients' abilities to  
8  
9 access and use healthcare and enact self-care, in turn effecting their health outcomes.<sup>19</sup> In  
10  
11 addition to worsening health outcomes, unaddressed workload-capacity imbalance can lead to a  
12  
13 vicious cycle of added treatment burden and illness burden.<sup>19</sup>  
14  
15  
16  
17

18 To date, the ICAN Discussion Aid remains untested in terms of its impact on the  
19  
20 discussion of patient workload, capacity, and treatment burden in the clinical encounter. We  
21  
22 hypothesize that if ICAN proves feasible in busy primary care and positively impacts the clinical  
23  
24 encounter with greater discussion of patients' context, it could spark treatment plans that better  
25  
26 fit patients' lives, with downstream impact on patient health outcomes and quality of life.  
27  
28  
29

### 30 *1.2. Aim*

31  
32  
33 We aimed to evaluate the feasibility of using the ICAN Discussion Aid in primary care  
34  
35 and to estimate its impact on clinical care, including patient and clinician-perceived success of  
36  
37 visits, length of visits, and topics of conversation.  
38  
39  
40

## 41 **2. Methods**

42  
43  
44 To pilot test the ICAN Discussion Aid, we conducted a pre-test versus post-test  
45  
46 intervention study.  
47  
48

### 49 *2.1. Ethics*

50  
51  
52 All study procedures were approved by the Mayo Clinic IRB (14-008621); patient and  
53  
54 clinician participants consented for data collection procedures.  
55  
56  
57  
58  
59  
60

## 2.2. Participant Eligibility and Recruitment

Clinicians were recruited from two clinical sites in the Midwest and were eligible for participation if they regularly saw patients with chronic conditions. Clinicians were consented for participation either at a lunch-hour clinical practice meeting or immediately before their first eligible patient. Adult patients were eligible if they had one or more chronic conditions, no major barriers to consent (e.g. cognitive impairment), and were seeing a clinician who had agreed to participate. Patients were approached immediately before the encounter with their clinician.

## 2.3 Study Procedures

After both clinician and patient were enrolled in the study, a trained study coordinator set up a small video camera (i.e., FlipCam, GoPro) to record the clinic visit. Patients and clinicians could turn the video camera off at any time if they felt uncomfortable, and the video camera was always turned around or off during physical exams. Following the encounter, both patient and clinician were given a survey to complete immediately or return in a postage-paid return envelope. The study coordinator followed-up on surveys not returned within one week. The first 40 clinical encounters were usual care. After the first 40 encounters, clinicians were then trained during a standing meeting or individually on how to use the ICAN Discussion Aid. The remaining 60 clinical encounters were intended to be ICAN encounters.

## 2.4. Intervention: The ICAN Discussion Aid

The study coordinator provided instructions for the patient to complete the ICAN Discussion Aid (**Figure 1**) before the clinician entered the room. When the clinician entered the room, he or she would select one of three opening questions to elicit responses from the patient, and would then explore the information that the patient provided in ICAN by asking “What

1  
2  
3 stands out to you on this sheet you filled?” Clinicians were instructed to discuss that issue alone  
4  
5 and connect it to the reason for the visit that day. Clinical conversation was expected to proceed  
6  
7 as usual with incorporation of the ICAN information.  
8  
9

## 10 2.5. Measures

11  
12  
13 Clinician degree, position, and gender were collected at baseline. Patient characteristics  
14  
15 of age, sex and marital status were abstracted from the medical record. To assess *perceived*  
16  
17 *success* of the encounter, we used the Consultation Care Measure (CCM), a valid and  
18  
19 discriminating tool to measure communication and partnership within a single encounter,  
20  
21 previously correlated with patient satisfaction, enablement, and reduced symptom burden.<sup>20</sup> The  
22  
23 measure asks patients to what extent they agree with statements about the doctor such as he/she  
24  
25 “was interested in what I thought the problem was.”<sup>20</sup> For clinician surveys, we used a modified  
26  
27 version of the patient CCM, adjusted to the clinician perspective, which was not previously  
28  
29 validated. For example, the patient might be asked the extent to which they felt the clinician  
30  
31 “was careful to explain the plan of treatment.” Whereas the clinician would be asked the extent  
32  
33 to which they agreed with the statement that they felt that they “were careful to explain the plan  
34  
35 of treatment.” To assess *feasibility* of ICAN use, we asked clinicians to report how easy or  
36  
37 difficult the aid was to use in their encounter on a 5-point scale, from very easy to very difficult.  
38  
39 If clinicians marked difficult or very difficult, they were prompted to write a brief description of  
40  
41 why. To assess *adherence*, patients pharmaceutical records were collected as a means to provide  
42  
43 estimates of baseline adherence amongst patients in this population, and of whether using ICAN  
44  
45 potentially effects adherence through the tailoring of patient care plans to their life context.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

## 2.6. Videographic Coding Scheme

To assess ICAN's *impact on clinical conversation topics*, we created an a priori video coding scheme, in which we coded each instance where the following topics were brought up: family, friends, free time, faith, living situation, being active, rest, comfort, emotional life, senses, memory, eating well, taking medications, making appointments, getting to appointments, administrative treatment work (e.g., dealing with insurance/billing, communicating with pharmacies), prescribed behaviors (e.g. getting mammograms, exercising a certain number of minutes per week), and other treatment work (i.e, work that the patient was asked to do but that did not fit into these other categories). Life issues listed in the coding scheme were those shown on ICAN and previously illustrated as important components of patient capacity from earlier work.<sup>17,21</sup> Treatment burden issues listed in the coding scheme were derived from typical issues listed in the development of ICAN and a taxonomy of treatment burden.<sup>17,22</sup> We also coded for opening questions typically used in ICAN, designed to elicit the existence of competing priorities that could potentially limit the capacity for self-care or treatment, sources of joy in patients' lives, and immediate concerns (medical and non-medical). To assess *impact on length of visit*, we compared lengths of video recording.

## 2.7. Analyses

All statistical analyses were conducted in SAS (SAS Institute Inc., Version9.4, Cary, NC, USA) and Stata (StataCorp, Release 15. College Station, TX). Videographic coding was done using Noldus Observer XT (version 11, Leesburg, VA). Patient and clinical encounter characteristics were compared between ICAN and control encounters using a t-test for continuous variables and a chi-square test for categorical variables. To explore differences in



1  
2  
3 patient and clinician perceived success of an encounter, we subtracted unadjusted clinician  
4  
5 scores from unadjusted patient scores, and tested for changes in the perceived success gap  
6  
7 between ICAN and control encounters using a Wilcoxon Rank-Sum test. To test for differences  
8  
9 across issues discussed in videos where patients and clinicians used ICAN versus those recorded  
10  
11 in control encounters, we used a negative binomial model accounting for clustering within  
12  
13 clinicians.  
14  
15

## 16 17 18 *2.8 Patient and Public Involvement*

19  
20  
21 The Knowledge and Evaluation Research Unit Patient Advisory Group participated in the  
22  
23 design of the ICAN Discussion Aid, ensuring its relevance to patients living with chronic  
24  
25 conditions and its ease of use. They were not consulted for the research design of the pilot study.  
26  
27

## 28 **3. Results**

29  
30  
31 Eleven clinicians were enrolled from two primary care clinics within the Midwest, United  
32  
33 States starting in October 2015. Seven clinicians approached declined enrollment, without  
34  
35 providing a reason. The clinicians were primarily female (N=7, 64%) and were primarily  
36  
37 physicians, with one nurse practitioner and two physician assistants. Patient enrollment began  
38  
39 October 2015 and ended February 2017. 100 patients consented to participate (ICAN n=60).  
40  
41 Detailed enrollment information is depicted in **Figure 2**. Of the eleven clinicians participating,  
42  
43 one had all control encounters and five had all ICAN encounters. Patient characteristics are  
44  
45 depicted in **Table 1**. Encounter length did not significantly differ between ICAN and control  
46  
47 encounters.  
48  
49  
50

### 51 52 53 *3.1. Clinician reported feasibility of ICAN*

1  
2  
3 Clinicians found the tool feasible to use in the majority of encounters. 62% reported it  
4 very easy or easy, 32% reported it as neither easy nor difficult, and 5% reported it was difficult  
5 to use in that encounter. There were two encounters where it was reported as difficult by  
6 different clinicians. For one encounter the clinician stated, "Unfortunately, this made her  
7 appointment go over by about 30 minutes. It was good we discussed issues with the portal [*an*  
8 *online platform that allows patients to access their health information*] and her life and stressors  
9 but it wasn't a big concern (why it wasn't a reason for the appointment) but we spent a good deal  
10 of time on it." Upon further review of this video, it appears that the primary reason that the  
11 encounter lasted substantially longer than planned was a lack of fidelity to ICAN training. After  
12 the clinician asked the patient what stood out to her from ICAN, she continued to elicit  
13 information about each burden listed by the patient, rather than connect the patient's response to  
14 the remainder of the clinical visit. Addressing the two key issues the patient brought up, work  
15 stress and being active, took approximately five and a half minutes in total. Following that, the  
16 clinician spent an additional five and a half minutes reviewing the other items on the tool.

17  
18  
19 In the second encounter, the clinician stated, "I enjoy the learning and conversation  
20 obtained from form [*sic*] but didn't have the extra time in schedule [*sic*] necessary to address  
21 each issue - easily added another 15-20 minutes to appointment." In this encounter, the patient  
22 indicated that her emotional life was both a source of satisfaction and a burden. The clinician  
23 enquired further and thus provided the patient with an opportunity to talk about her prolonged  
24 grief after the loss of her spouse and her concerns about possible depression. In response the  
25 clinician screened the patient for potential depression. Total time using the tool and discussing  
26 that issue took four minutes of the total visit. The patient was scheduled for a 45 minute general  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 medical exam, and the total video recorded visit time was 26 minutes, which did not include the  
4  
5 physical exam at the end of the encounter.  
6  
7

### 8 9 *3.2. Survey Results*

10  
11 We did not find any items with significant differences between patients in either cohort  
12 for the consultation care measure (**Table 2**). When comparing patients and clinicians across the  
13 consultation care measure, among the items that overlapped, clinicians tended to score  
14 themselves poorer than patients. This was more prevalent when the ICAN tool was used (**Table**  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### *3.3. Videographic Results*

Issues discussed during clinical encounters did significantly differ between ICAN and control encounters in multiple domains (**Table 4**). Specifically, discussions about being active, diet, and taking medications were discussed significantly more frequently in ICAN encounters. Discussions about administrative treatment work, other treatment work, family, living arrangements, and comfort were discussed significantly less frequently in ICAN encounters. We noticed that often topics about family were used as conversation fillers in control encounters, whereas there may have been less room for this when patients were prompted to bring up issues that mattered most to them.

## **4. Discussion and Conclusion**

### *4.1. Summary of Findings*

1  
2  
3 Within this pilot trial, clinicians found the ICAN Discussion Aid to be a tool they could  
4 feasibly adopt into everyday practice and which did not impact the length of the visit. Patients  
5 discussed diet, being active, and taking medications more often in ICAN encounters.  
6  
7

8  
9  
10 Additionally, clinicians elicited competing priorities using ICAN opening questions that were  
11 never elicited during the opening of control encounters. While clinicians rated the perceived  
12 success of their encounters poorer than their patients (CCM score), and the gap between patient  
13 and clinician perceived success was larger ICAN encounters, the difference was not significant.  
14  
15  
16  
17  
18  
19 No difference was seen for adherence to prescription medications.  
20  
21

#### 22 *4.2. Limitations and Strengths*

23  
24

25 These findings cannot be interpreted without considering the limitations in this study  
26 design. First, this study was a small before-after pilot study which limits our ability to draw  
27 statistical inferences that would be possible in a larger trial with a randomized design. The study  
28 was not powered to assess clinical significance for patient-reported outcomes nor prescription  
29 adherence and a lack of difference found is not indicative of one not existing. Furthermore, the  
30 study occurred within a single healthcare system in the Midwest with a fairly homogenous  
31 patient population of mostly high or middle socioeconomic status, which limits the  
32 generalizability of the specific changes in topics present in ICAN conversations versus usual care  
33 conversations. However, the small size of the study allowed us to pursue video-recording of all  
34 encounters, which allowed for deeper exploration of ICAN's impact on conversations and to  
35 point to additional needs for future implementation and testing of ICAN in practice that would  
36 have been more difficult in a larger multi-site study.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

#### 53 *4.3. Practice Implications*

54  
55  
56  
57  
58  
59  
60

1  
2  
3 Feasibility of ICAN use is an important finding on its own, given previously reported  
4 challenges by clinicians in providing patient-centered care and participating in shared decision  
5 making for populations living with MCC.<sup>23</sup> Furthermore, the difference in the topics brought up  
6 in ICAN encounters suggests that patients are indeed more likely to be able to voice their topics  
7 of choice, in an area where poor communication has been a noted frustration amongst patients.<sup>24</sup>  
8 Diet, being active, and taking medications are not surprising topics to be most important to  
9 patients in this setting and population (suburban, Midwest, academic medical center). However,  
10 these topics have been noted as important treatment burden factors for patients in other diverse  
11 samples; patients noted that they were aware their clinicians wanted them to eat healthier or  
12 exercise more frequently, but important barriers existed of which their clinicians were unaware.<sup>25</sup>  
13 Furthermore, in a previous study of patient-clinician concordance, patients were more likely than  
14 clinicians to rank being active as one of their top three health concerns.<sup>26</sup> Future research should  
15 examine whether the topics discussed more often are different in other clinical settings (e.g. rural  
16 and urban), with different populations (e.g. unsalaried clinicians, underserved patients), and what  
17 clinicians can do in clinical encounters with this information.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 Ultimately, the discussion of topics of greater importance to patients and their competing  
39 priorities is important as it could lead to better tailoring of treatment plans to patients' context,  
40 improving patients' workload-capacity balance in managing chronic illness. As mentioned  
41 earlier, the Cumulative Complexity Model postulates that workload-capacity balance impacts  
42 patients' abilities to access and use healthcare and enact self-care, with downstream impact on  
43 their health outcomes.<sup>19</sup> Furthermore, communication models, such as the one proposed by Street  
44 et al. have postulated the pathways from patient-clinician communication to patient outcomes.<sup>27</sup>  
45 For example, Street's model illustrates that communication functions supported by ICAN such as  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 managing uncertainty, fostering relationships, and enabling self-management can impact  
4 proximal outcomes such as patient trust and “feeling known,” with downstream consequences on  
5 self-care skills, adherence, and ultimately health outcomes.<sup>27</sup> ICAN is a general discussion aid  
6 for use in chronic illness, intended to provide insight into the personal, social, material, and  
7 spiritual aspects of the patient’s situation; it can be used in conjunction with the many available  
8 decision-specific conversation aids.<sup>28</sup> For example, an ICAN conversation may illuminate that a  
9 patient finds their overall medication regimen particularly burdensome, and this may spark a  
10 treatment-specific conversation about choosing a different treatment in replacement of a current  
11 one or inform the decision to add or not add another medication to the list. A good example of  
12 the use of ICAN and a treatment decision aid is available on the web.<sup>29</sup> Used in this way,  
13 clinicians may fully understand patients’ competing priorities as well as treatment-specific  
14 values and preferences, and therefore, be able to co-create with them treatment plans that fit their  
15 context and allow them to lead quality lives to the fullest extent.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

34 Examining the two encounters noted as difficult for clinicians yielded important  
35 information about ICAN implementation challenges. The encounter where additional time was  
36 used to discuss all ICAN items suggests that additional training may be needed for clinicians to  
37 illustrate how to connect the initial question of “What stands out to you?” to the clinical reason  
38 for the appointment, and how to continue the use of the discussion aid at future encounters. In  
39 the encounter in which the patient was able to discuss potential concerns of depression, the  
40 clinician noted that this added an additional 15 – 20 minutes to the encounter, whereas the actual  
41 discussion took less than five minutes. The perceived duration may have felt longer than the  
42 actual duration because of the heavy nature of the topic discussed. Past research in primary care  
43 patients with multi-morbidity has shown that clinician comfort level with these types of difficult  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 topics is low and that in practicing a traditional “additive-sequential model,” where each problem  
4  
5 is treated independently and prioritized, these issues may never get acknowledged.<sup>15,30</sup> Therefore,  
6  
7 the implementation of ICAN can provide an opportunity to train clinicians to address potentially  
8  
9 difficult topics, manage their expectations of those discussions, and learn how to successfully  
10  
11 have those conversations. Specifically, this requires attention and clinician exposure in future  
12  
13 ICAN trainings to the potentially uncomfortable and off-script conversations that may occur as a  
14  
15 result of using the aid, as well as practice in having those conversations first in safe spaces, such  
16  
17 as with peers and trainers, prior to real-life clinical encounters.  
18  
19  
20  
21

#### 22 *4.4. Conclusion*

23  
24  
25 In conclusion, we successfully pilot tested the ICAN Discussion Aid in primary care  
26  
27 encounters. This study illustrated that ICAN was perceived as feasible to implement in normal  
28  
29 clinical practice, did not impact visit length, and impacted the conversation topics discussed in  
30  
31 encounters. While patients perceived improved visit success with ICAN use, clinicians perceived  
32  
33 worsened visit success. Clinical encounters that were noted as difficult to use ICAN point to  
34  
35 additional ICAN training needs in future implementation and study settings. ICAN deserves  
36  
37 further testing to determine if its implementation leads to better workload-capacity balance for  
38  
39 patients living with chronic illness and if this translates to improved patient health outcomes.  
40  
41  
42  
43

#### 44 *Authors' contributions*

45  
46  
47 KRB was responsible for study design, overall study execution, analysis, and the draft  
48  
49 manuscript. CCD and AT conducted videographic analysis and provided critical revisions for the  
50  
51 manuscript. MB and RG conducted statistical analysis, created tables, and drafted the statistical  
52  
53 sections of the manuscript. EB was responsible for study coordination of the study and data  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 collection procedures. PO assisted with data cleaning procedures, drafting of the manuscript, and  
4  
5 critical revisions to the manuscript. SVA served as clinical champion for the study and provided  
6  
7 critical revisions to the manuscript. KS provided revisions to the manuscript and data  
8  
9 visualization. VMM assisted KRB with study design and oversight of the project.  
10  
11  
12

### 13 *Conflicts of Interests*

14  
15  
16 The authors of this manuscript have no conflicts of interests to report.  
17  
18

### 19 *Funding Statement*

20  
21  
22 This research was supported in part by an internal award from the Mayo Clinic Robert and  
23  
24 Arlene Kogod Center for Aging.  
25  
26  
27

### 28 *Data Availability*

29  
30  
31 All data for this study are published within this manuscript and its supplementary materials. No  
32  
33 additional unpublished data is available.  
34  
35

### 36 *Included Figures*

37  
38  
39 Figure 1: ICAN Discussion Aid  
40  
41  
42

43 Figure 2: Detailed Enrollment Information  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## References

1. Centers for Disease Control. Chronic Diseases: The Leading Causes of Death and Disability in the United States. <https://www.cdc.gov/chronicdisease/overview/>. Published 2017. Accessed May 17, 2018.
2. Ward BW, Schiller JS. Prevalence of multiple chronic conditions among US adults: estimates from the National Health Interview Survey, 2010. *Prev Chronic Dis*. 2013;10:E65.
3. Eton DT, Ramalho de Oliveira D, Egginton JS, et al. Building a measurement framework of burden of treatment in complex patients with chronic conditions: a qualitative study. *Patient related outcome measures*. 2012;3:39-49.
4. Ridgeway JL. Factors that lessen the burden of treatment in complex patients with chronic conditions: A qualitative study. In:2013.
5. Wyatt KD, Stuart LM, Brito JP, et al. Out of context: clinical practice guidelines and patients with multiple chronic conditions: a systematic review. *Med Care*. 2014;52 Suppl 3:S92-S100.
6. Gallacher K, May CR, Montori VM, Mair FS. Understanding patients' experiences of treatment burden in chronic heart failure using normalization process theory. *Annals of family medicine*. 2011;9(3):235-243.
7. Gallacher K, Morrison D, Jani B, et al. Uncovering treatment burden as a key concept for stroke care: a systematic review of qualitative research. *PLoS medicine*. 2013;10(6):e1001473.
8. Shippee ND, Shippee TP, Hess EP, Beebe TJ. An observational study of emergency department utilization among enrollees of Minnesota Health Care Programs: financial and non-financial barriers have different associations. *BMC health services research*. 2014;14:62.
9. May C, Montori VM, Mair FS. We need minimally disruptive medicine. *BMJ*. 2009;339:b2803.
10. May CR, Eton DT, Boehmer K, et al. Rethinking the patient: using Burden of Treatment Theory to understand the changing dynamics of illness. *BMC health services research*. 2014;14:281.
11. Bodenheimer T, Chen E, Bennett HD. Confronting the growing burden of chronic disease: can the U.S. health care workforce do the job? *Health affairs*. 2009;28(1):64-74.
12. Bayliss EA, Ellis JL, Steiner JF. Seniors' self-reported multimorbidity captured biopsychosocial factors not incorporated into two other data-based morbidity measures. *Journal of clinical epidemiology*. 2009;62(5):550-557 e551.
13. Cottrell E, Yardley S. Lived experiences of multimorbidity: An interpretative meta-synthesis of patients', general practitioners' and trainees' perceptions. *Chronic illness*. 2015;11(4):279-303.
14. Loeb DF, Binswanger IA, Candrian C, Bayliss EA. Primary care physician insights into a typology of the complex patient in primary care. *Annals of family medicine*. 2015;13(5):451-455.
15. O'Brien R, Wyke S, Guthrie B, Watt G, Mercer S. An 'endless struggle': a qualitative study of general practitioners' and practice nurses' experiences of managing multimorbidity in socio-economically deprived areas of Scotland. *Chronic illness*. 2011;7(1):45-59.
16. Safford MM. The Complexity of Complex Patients. *Journal of general internal medicine*. 2015;30(12):1724-1725.
17. Boehmer KR, Hargraves IG, Allen SV, Matthews MR, Maher C, Montori VM. Meaningful Conversations in Living with and Treating Chronic Conditions: Development of the ICAN Discussion Aid. *BMC health services research*. 2016.

18. Breslin M, Mullan RJ, Montori VM. The design of a decision aid about diabetes medications for use during the consultation with patients with type 2 diabetes. *Patient education and counseling*. 2008;73(3):465-472.
19. Shippee ND, Shah ND, May CR, Mair FS, Montori VM. Cumulative complexity: a functional, patient-centered model of patient complexity can improve research and practice. *Journal of clinical epidemiology*. 2012;65(10):1041-1051.
20. Little P, Everitt H, Williamson I, et al. Observational study of effect of patient centredness and positive approach on outcomes of general practice consultations. *BMJ*. 2001;323(7318):908-911.
21. Boehmer KR, Gionfriddo MR, Rodriguez-Gutierrez R, et al. Patient capacity and constraints in the experience of chronic disease: a qualitative systematic review and thematic synthesis. *BMC family practice*. 2016;17(1):127.
22. Tran VT, Barnes C, Montori VM, Falissard B, Ravaud P. Taxonomy of the burden of treatment: a multi-country web-based qualitative study of patients with chronic conditions. *BMC medicine*. 2015;13:115.
23. Academy of Medical Sciences. Multimorbidity: A priority for global health research. <https://acmedsci.ac.uk/policy/policy-projects/multimorbidity>. Published 2018. Accessed June 6, 2018.
24. Gill A, Kuluski K, Jaakkimainen L, Naganathan G, Upshur R, Wodchis WP. "Where do we go from here?" Health system frustrations expressed by patients with multimorbidity, their caregivers and family physicians. *Health Policy*. 2014;9(4):73-89.
25. Eton DT, Ridgeway JL, Egginton JS, et al. Finalizing a measurement framework for the burden of treatment in complex patients with chronic conditions. *Patient Relat Outcome Meas*. 2015;6:117-126.
26. Zulman DM, Kerr EA, Hofer TP, Heisler M, Zikmund-Fisher BJ. Patient-provider concordance in the prioritization of health conditions among hypertensive diabetes patients. *J Gen Intern Med*. 2010;25(5):408-414.
27. Street RL, Jr., Makoul G, Arora NK, Epstein RM. How does communication heal? Pathways linking clinician-patient communication to health outcomes. *Patient education and counseling*. 2009;74(3):295-301.
28. Stacey D, Legare F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. *Cochrane Database Syst Rev*. 2017;4:CD001431.
29. Mayo Clinic. My Life, My Healthcare (ICAN) and Statin Choice used in a single visit. <https://www.youtube.com/watch?v=a0H9RRGIFJg>. Published 2017. Accessed May 8, 2019.
30. Bower P, Macdonald W, Harkness E, et al. Multimorbidity, service organization and clinical decision making in primary care: a qualitative study. *Fam Pract*. 2011;28(5):579-587.

	ICAN (N=57*)	Pre-Intervention (N=40)	Total (N=97)	p value
<b>Sex</b>				0.09
Female	40 (70.2%)	34 (85.0%)	74 (76.3%)	
<b>Age: Mean (SD)</b>	62.7 (12.0)	66.8 (15.0)	64.4 (13.4)	0.05
<b>Marital status</b>				0.37
Divorced	11 (19.3%)	3 (7.5%)	14 (14.4%)	
Married	36 (63.2%)	27 (67.5%)	63 (64.9%)	
Single	5 (8.8%)	4 (10.0%)	9 (9.3%)	
Widowed	5 (8.8%)	6 (15.0%)	11 (11.3%)	
<b>Length of encounter (minutes): Mean (SD)</b>	31.6 (13.4)	34.5 (11.7)	32.9 (12.7)	0.25
Median (Q1, Q3)	31.3 (19, 41)	34.3 (25, 44)	33.6 (22, 42)	

<sup>^</sup>All enrolled patients.

\*3 patients in intervention missing data on characteristics.

**Table 2: CCM Patient Scores**

	ICAN (N=42)	Pre-Intervention (N=39)	Total (N=81)
<b>Overall score</b>			
Mean (SD)	29.7 (11.0)	28.6 (12.4)	29.2(11.6)
Median (Range)	25 (21, 62)	23 (21, 74)	24 (21, 74)
Adjusted mean* (95% CI)	31.5 (24.6, 38.5)	34.6 (29.3, 42.9)	

\*Adjusted by clinician clustering; lower scores = better

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2019-029105 on 3 September 2019. Downloaded from <http://bmjopen.bmj.com/> on April 23, 2024 by guest. Protected by copyright.

**Table 3: Clinician – Patient Difference in individual CCM scores**

	ICAN (N=38)*	Pre-Intervention (n=39)*	P-Value
1/E: Careful to explain	0.87 (0.52, 1.22)	0.64 (0.32, 0.96)	0.33
2/F: Was sympathetic	0.97 (0.57, 1.37)	0.54 (0.19, 0.89)	0.09
3/H: discussed & agreed together what problem was	0.97 (0.61, 1.33)	0.51 (0.19, 0.84)	0.047
4/K: discussed & agreed on plan of treatment	0.84 (0.51, 1.17)	0.59 (0.25, 0.93)	0.26
5/M: understood emotional needs	0.97 (0.43, 1.52)	0.77 (0.39, 1.15)	0.31
6/N: confident knows patient history	0.66 (0.23, 1.09)	0.77 (0.40, 1.14)	0.91
7/T: interested in effect of problem on family and personal life	0.68 (0.22, 1.15)	0.64 (0.27, 1.02)	0.73
8/U: interested in effect of problem on everyday life	0.82 (0.35, 1.29)	0.74 (0.39, 1.10)	0.60
Mean (95% CI), p-value Wilcoxon rank sum test			

\* Difference in scores calculated as clinician score minus patient score for encounter. Higher scores correspond to lower performance on the CCM tool.

	Behaviors *	All Encounters (n=84/ICAN= 45)		Patients (n=84)		Clinicians (n=84)	
		IRR (95% CI)	P value	IRR (95% CI)	P value	IRR (95% CI)	P value
<b>More likely with ICAN</b>	<b>Being active</b>	<b>1.52 (1.09, 2.11)</b>	<b>0.01</b>	<b>1.58 (1.12, 2.22)</b>	<b>0.008</b>	1.45 (0.95, 2.21)	0.09
	<b>Taking medications</b>	1.22 (0.99, 1.51)	0.06	<b>1.42 (1.20, 1.67)</b>	<b>&lt;.0001</b>	1.12 (0.85, 1.46)	0.42
	<b>Diet</b>	<b>2.02 (1.22, 3.32)</b>	<b>0.005</b>	<b>2.32 (1.39, 3.88)</b>	<b>0.001</b>	1.61 (0.93, 2.79)	0.09
	<b>Competing priorities</b>	<b>14.46 (4.00, 52.24)</b>	<b>&lt;.0001</b>	---**	---	<b>10.91 (3.63, 32.73)</b>	<b>&lt;.0001</b>
<b>Less Likely with ICAN</b>	<b>Other admin</b>	<b>0.56 (0.39, 0.82)</b>	<b>0.002</b>	0.74 (0.48, 1.13)	0.16	<b>0.47 (0.33, 0.69)</b>	<b>&lt;.0001</b>
	<b>Family</b>	<b>0.57 (0.36, 0.90)</b>	<b>0.02</b>	0.66 (0.42, 1.03)	0.05	<b>0.46 (0.28, 0.75)</b>	<b>0.002</b>
	<b>Faith</b>	<b>0.59 (0.42, 0.82)</b>	<b>0.002</b>	0.78 (0.44, 1.39)	0.41	0.36 (0.12, 1.05)	0.06
	<b>Senses</b>	<b>0.55 (0.30, 1.00)</b>	<b>0.05</b>	0.65 (0.35, 1.22)	0.18	<b>0.44 (0.23, 0.87)</b>	<b>0.02</b>
<b>No Difference with ICAN</b>	Other treatment work	0.90 (0.65, 1.24)	0.52	1.07 (0.71, 1.63)	0.74	0.77 (0.59, 1.01)	0.06
	Immediate concerns	1.11 (0.69, 1.76)	0.68	1.62 (0.86, 3.06)	0.14	0.90 (0.60, 1.37)	0.64
	Joy	---**	---	---**	---	---**	---
	Where I live	0.82 (0.50, 1.35)	0.44	1.09 (0.66, 1.80)	0.75	0.58 (0.32, 1.04)	0.07
	Comfort	0.76 (0.50, 1.16)	0.20	0.90 (0.62, 1.33)	0.61	0.63 (0.39, 1.01)	0.05
	Free time	1.08 (0.54, 2.16)	0.82	1.20 (0.60, 2.40)	0.61	0.96 (0.45, 2.04)	0.92
	Making appointments	0.76 (0.50, 1.16)	0.21	0.77 (0.49, 1.23)	0.27	0.75 (0.49, 1.15)	0.18
	Prescribed behaviors	0.84 (0.45, 1.58)	0.59	0.96 (0.57, 1.64)	0.89	0.80 (0.40, 1.61)	0.53
	Friends	0.75 (0.33, 1.66)	0.47	0.65 (0.30, 1.40)	0.27	1.41 (0.52, 3.75)	0.49
	Getting to appointments	1.24 (0.74, 2.08)	0.41	1.34 (0.76, 2.36)	0.32	1.09 (0.60, 2.00)	0.78
	Work	0.85 (0.60, 1.220)	0.39	1.05 (0.75, 1.47)	0.80	0.62 (0.38, 1.02)	0.06
	Rest	0.89 (0.52, 1.54)	0.68	0.92 (0.52, 1.59)	0.75	0.87 (0.46, 1.64)	0.67
	Emotional life	1.23 (0.54, 2.80)	0.63	1.56 (0.64, 3.83)	0.33	1.03 (0.41, 2.59)	0.95
	Volunteer	0.85 (0.30, 2.38)	0.76	0.57 (0.16, 2.04)	0.39	---**	---
	Personal meaning	2.39 (0.18, 32.56)	0.51	2.39 (0.18, 31.56)	0.51	---**	---
School	---**	---	---**	---	---**	---	
Memory	1.98 (0.70, 5.63)	0.20	2.41 (0.71, 8.25)	0.1596	0.80 (0.30, 2.13)	0.65	

IRR = Incidence Rate Ratio; >1 means more occurrences in ICAN encounters, <1 fewer occurrences in ICAN encounters

\*Adjusted for gender, age at enrollment, length of encounter and clustering around shared clinicians

\*\* Insufficient data for analysis

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



- What are you doing when you're not sitting here with me?
- Where do you find the most joy in your life?
- What's on your mind today?

These questions can help shift discussion towards the broader life of your patient. Use as many of them as you wish.

Are these areas of your life a source of satisfaction, burden, or both?

	Satisfaction	Burden
My family and friends	<input type="checkbox"/>	<input type="checkbox"/>
My work	<input type="checkbox"/>	<input type="checkbox"/>
Free time, relaxation, fun	<input type="checkbox"/>	<input type="checkbox"/>
Faith or personal meaning	<input type="checkbox"/>	<input type="checkbox"/>
Where I live	<input type="checkbox"/>	<input type="checkbox"/>
Getting out and transportation	<input type="checkbox"/>	<input type="checkbox"/>
Being active	<input type="checkbox"/>	<input type="checkbox"/>
My rest and comfort	<input type="checkbox"/>	<input type="checkbox"/>
My emotional life	<input type="checkbox"/>	<input type="checkbox"/>
My senses and memory	<input type="checkbox"/>	<input type="checkbox"/>
Eating well	<input type="checkbox"/>	<input type="checkbox"/>

What are the things that your doctors or clinic have asked you to do to care for your health?

Do you feel that they are a help, a burden, or both?

	Help	Burden
<i>example: come in for appointments</i>	<input type="checkbox"/>	<input type="checkbox"/>
<i>example: take aspirin</i>	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>



Figure 1: ICAN Discussion Aid

419x215mm (300 x 300 DPI)




Figure 2: Detailed Enrollment Information

215x279mm (300 x 300 DPI)



## Appendix 1: Pharmaceutical prescription methods and results

*Measure*

Patients' prescriptions that had been filled were obtained from their pharmacies directly. We collected information on patients' filled prescriptions six months prior to enrollment to six months post-enrollment. Adherence to treatment was assessed for the six months post-enrollment by calculating the percentage of days out of the 180 day period for which a patient had a filled prescription.[23] Medications to treat chronic conditions were considered for inclusion in analysis.

<b>Appendix Table 1: Included Medications</b>	
<b>Medication Class</b>	<b>Medication Name</b>
<b>ACE inhibitor</b>	<b>Enalapril Maleate</b>
	<b>Lisinopril</b>
	<b>Ramipril</b>
<b>Alpha blocker</b>	<b>Tamsulosin</b>
	<b>Tamsulosin HCL</b>
<b>Alpha1 adrenergic blocker</b>	<b>Doxazosin Mesylate</b>
<b>Alpha2 delta ligand</b>	<b>Lyrica</b>
<b>Aminoketone antidepressant</b>	<b>Bupropion</b>
	<b>Bupropion HCL</b>
	<b>Bupropion HCL ER</b>
	<b>Bupropion XL</b>
	<b>SR Bupropion</b>
<b>Angiotensin receptor blocker (ARB)</b>	<b>Candesartan</b>
	<b>Lorsartan Potassium</b>
	<b>Losartan</b>
	<b>Losartan -HCTZ</b>
	<b>Losartan HCTZ</b>
	<b>Losartan Potassium</b>
	<b>Losartan-HCTZ</b>
	<b>Valsartan</b>
<b>Antiandrogen</b>	<b>Bicalutamide</b>
<b>Antiarrhythmic drug</b>	<b>Amiodarone</b>
	<b>Flecainide Acetate</b>

<b>Appendix Table 1: Included Medications</b>	
<b>Medication Class</b>	<b>Medication Name</b>
<b>Anticoagulant</b>	<b>Enoxaparin Sodium</b>
	<b>Jantoven</b>
	<b>Warfarin Sodium</b>
	<b>Xarelto</b>
<b>Anticonvulsant</b>	<b>Carbamazepine</b>
	<b>Carbamazepine ER</b>
	<b>Gabapentin</b>
	<b>Lamotrigine</b>
	<b>Topiramate</b>
	<b>Zonisamide</b>
<b>Anxiolytic antianxiety agent</b>	<b>Buspirone</b>
<b>Atypical antipsychotic</b>	<b>Latuda</b>
	<b>Quetiapine</b>
	<b>Quetiapine Fumarate</b>
<b>Beta blocker</b>	<b>Atendlol Chlorthalidone</b>
	<b>Atenolol</b>
	<b>Bisoprolol</b>
	<b>Carvedilol</b>
	<b>ER Metoprolol</b>
	<b>Metoprolol ER</b>
	<b>Metoprolol ER Succinate</b>
	<b>Metoprolol SUCC ER</b>
	<b>Metoprolol Tart</b>
	<b>Metoprolol Tartrate</b>
<b>Metoprololhydrochloroth</b>	
<b>Biguanide</b>	<b>Timolol Maleate</b>
	<b>Metforman</b>
	<b>Metformin</b>
	<b>Metformin ER</b>
	<b>Metformin HCL</b>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

<b>Appendix Table 1: Included Medications</b>	
<b>Medication Class</b>	<b>Medication Name</b>
	<b>Metformin HCL ER</b>
	metformin
<b>Bisphosphonate</b>	<b>Alendronate</b>
	<b>Alendronate Sodium</b>
<b>Calcium channel blocker</b>	<b>Amlodipine</b>
	<b>Amlodipine Besylate</b>
	<b>Diltiazem HCL ER</b>
	<b>Nifedipine</b>
	<b>Verapamil HCR ER</b>
<b>Central alpha agonist</b>	<b>Clonidine HCL</b>
<b>Central muscle relaxant</b>	<b>Methocarbamol</b>
<b>Class 1b antiarrhythmic drug</b>	<b>Lidocaine</b>
<b>DDP4 inhibitor + biguanide</b>	<b>Janumet XR</b>
<b>Dibenzazepine</b>	<b>Tegretol XR</b>
<b>Digitalis glycoside</b>	<b>Digoxin</b>
<b>Disease modifying antirheumatic drug (DMARD)</b>	<b>Hydroxychloroquine Sulfate</b>
<b>Diuretic</b>	<b>Hydrochlorothiazide</b>
	<b>Hydrochlorothiazide</b>
	<b>Metolazone</b>
<b>Fibric acid</b>	<b>Fenofibrate</b>
	<b>Fenofibrate Micronized</b>
<b>Janus kinase (JAK) inhibitors</b>	<b>Xeljanz</b>
<b>Leukotriene receptor antagonists</b>	<b>Montelukast Sodium</b>
<b>Loop diuretic</b>	<b>Furobemide</b>
	<b>Furosemide</b>
	<b>Torsemide</b>
<b>Nitrate</b>	<b>Isosorb Mono ER</b>
	<b>Isosorbide MN ER</b>
<b>Nonergoline dopamine agonist</b>	<b>Pramipexole</b>
<b>Oral diuretic</b>	<b>Triamterene-HCTZ</b>

<b>Appendix Table 1: Included Medications</b>	
<b>Medication Class</b>	<b>Medication Name</b>
<b>P2Y12 inhibitor</b>	<b>Clopidogrel</b>
	<b>Clopidogrel Bisulfate</b>
<b>Phenylpiperazine antidepressant</b>	<b>Nefazodone HCL</b>
<b>Phosphodiesterase 4 (PDE4) inhibitors</b>	<b>Otezla</b>
<b>Potassium sparing diuretic</b>	<b>Spirolactone</b>
<b>SNRI</b>	<b>Desvenlafaxine ER</b>
	<b>Duloxetine DR</b>
	<b>Duloxetine HCL</b>
	<b>Duloxetine Hcl</b>
	<b>ER Venlafaxine</b>
	<b>Escitalopram Oxalate</b>
	<b>Venlafaxine XR</b>
	<b>Venlafaxin XR</b>
	<b>Venlafaxine ER</b>
	<b>Venlafaxine HCL ER</b>
<b>SSRI</b>	<b>Citalopram</b>
	<b>Citalpram</b>
	<b>Fluoxetine</b>
	<b>Fluoxetine HCL</b>
	<b>Paroxetine</b>
	<b>Paroxetine HCL</b>
	<b>Sertraline</b>
	<b>Sertraline HCL</b>
<b>Selective estrogen receptor modulator (SERM)</b>	<b>Raloxifene HCL</b>
	<b>Tamoxifen</b>
<b>Statin</b>	<b>Atorvastatin</b>
	<b>Atorvastatin Calcium</b>
	<b>Locastatin</b>
	<b>Lovastatin</b>

<b>Appendix Table 1: Included Medications</b>	
<b>Medication Class</b>	<b>Medication Name</b>
	<b>Pravastatin Sodium</b>
	<b>Rosuvastatin Calcium</b>
	<b>Simvastatin</b>
	<b>Vytorin</b>
<b>Sulfonylurea</b>	<b>Climepiride</b>
	<b>Glimepiride</b>
	<b>Glipizide</b>
	<b>Glipizide ER</b>
	<b>Glipizide XL</b>
<b>Tetracyclic antidepressant</b>	<b>Mirtazapine</b>
<b>Thiazide diuretic</b>	<b>Chlorthalidone</b>
<b>Thyroxine; T4 (synthetic)</b>	<b>Levothroxine</b>
	<b>Levothyroxine</b>
	<b>Levothyroxine SOD</b>
	<b>Synthroid</b>
<b>Triazolopyridine antidepressant</b>	<b>Trazodone HCL</b>
<b>Tricyclic antidepressant</b>	<b>Amitriptyline HCL</b>
	<b>Cyclobenzaprine HCL</b>
	<b>Cyclovenzaprine HCL</b>
	<b>Cyclovenzaprine HCL</b>
	<b>Nortriptyline</b>
	<b>Nortriptyline</b>
	<b>Nortriptyline HCL</b>
<b>Triiodothyronine</b>	<b>Liothyronine Sodium</b>
<b>Valeric acid</b>	<b>Gemfibrozil</b>
<b>Missing</b>	<b>Missing</b>
<b>Other / Unknown</b>	<b>Amsulosin</b>
	<b>Isometh-apap-dichlor-</b>
	<b>Metromin HCL</b>
	<b>Oxycodone 5MG IR Tabs</b>

### Statistical Analysis

Adherence to medications was assessed by medication class (i.e. if patient had multiple medications within a class, average adherence was calculated). Adherence was modeled using a hierarchical generalized linear model where the outcome was a patients' medication class adherence six months post enrollment. The model was clustered by patient, as patients could have multiple classes of medication, and adjusted by their adherence to the medication class in the six months prior to enrollment and intervention arm. Patients who did not have the medication class in the prior period were set to zero for baseline and a missing indicator was assessed in the model to address this. Patients with missing pharmacy data (e.g. their pharmacy

### Adherence Results

Similar rates of medication counts, medication classes and adherence were seen between groups in the six months prior to the encounter of interest (76% of days covered in patients in the ICAN group vs. 71% control) was unreachable for data request) were not included in the analysis.

<b>Appendix Table 2: Analysis of percent of days covered of medication classes by intervention.</b>			
	ICAN (N=53)	Pre- Intervention (N=27)	p value
<b>Count of medications prior to encounter</b>			0.57
Mean (SD)	3.6 (2.6)	4.2 (3.3)	
Median (IQR)	3 (2, 5)	4 (2, 5)	
<b>Count of medication classes prior to encounter</b>			0.54
Mean (SD)	3.4 (2.3)	3.9 (2.9)	
Median	3 (1, 5)	4 (2, 5)	
<b>Adherence (PDC) prior to encounter</b>			0.94
Mean (95% CI)	55% (50, 60)	54% (50, 60)	
<b>Count of medications post encounter</b>			0.37
Mean (SD)	3.8 (2.5)	4.1 (2.0)	
Median	3 (2, 5)	4 (3, 5)	
<b>Count of medication classes post encounter</b>			0.36
Mean (SD)	3.6 (2.3)	3.9 (1.8)	
Median	3 (2, 5)	4 (3, 5)	

<b>Appendix Table 2: Analysis of percent of days covered of medication classes by intervention.</b>			
	ICAN (N=53)	Pre- Intervention (N=27)	p value
<b>Adherence (PDC) post encounter</b>			0.56
Mean (95% CI)	75% (70, 80)	71% (60, 80)	
<b>Adjusted adherence (PDC) post encounter<sup>^</sup></b>			0.43
Mean (95% CI)	76% (70, 80)	72% (60, 80)	

Acronym: PDC Percent of Days Covered

\* Prior and post encounter periods are each 6 months long.

<sup>^</sup> ANCOVA with random effect of clinician and adjusted by prior 6 months adherence and intervention.

# BMJ Open

## Changing Conversations in Primary Care for Patients Living with Chronic Conditions: A Pilot and Feasibility Study of the ICAN Discussion Aid

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029105.R2
Article Type:	Research
Date Submitted by the Author:	12-Jul-2019
Complete List of Authors:	Boehmer, Kasey R.; Mayo Clin, Dobler, Claudia; Mayo Clin, Knowledge and Evaluation Research Unit; 2. Evidence-Based Practice Center, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery Thota, Anjali; Mayo Clin, Knowledge and Evaluation Research Unit Branda, Megan; Mayo Clinic, Health Sciences Research Giblon, Rachel; Mayo Clin, 3. Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery Behnken, Emma; Mayo Clin, Knowledge and Evaluation Research Unit Organick, Paige; Mayo Clin, Knowledge and Evaluation Research Unit Allen, Summer; Mayo Clin, Knowledge and Evaluation Research Unit; Department of Family Medicine Shaw, Kevin; Mayo Clin, Knowledge and Evaluation Research Unit Montori, Victor; Mayo Clinic, Knowledge and Encounter Research Unit
<b>Primary Subject Heading</b>:	Patient-centred medicine
Secondary Subject Heading:	Communication
Keywords:	patient-centered care, minimally disruptive medicine, healthcare communication, chronic disease, multimorbidity

SCHOLARONE™  
Manuscripts



## Changing Conversations in Primary Care for Patients Living with Chronic Conditions: A Pilot and Feasibility Study of the ICAN Discussion Aid

Kasey R. Boehmer, PhD, MPH<sub>1</sub> ([Boehmer.kasey@mayo.edu](mailto:Boehmer.kasey@mayo.edu))

Claudia C. Dobler, MD, PhD<sub>1,2</sub> ([Dobler.claudia@mayo.edu](mailto:Dobler.claudia@mayo.edu))

Anjali Thota, BA<sub>1</sub> ([Thota.anjali@mayo.edu](mailto:Thota.anjali@mayo.edu))

Megan Branda, MS<sub>3</sub> ([Branda.megan@mayo.edu](mailto:Branda.megan@mayo.edu))

Rachel Giblon, MS<sub>3</sub> ([Giblon.rachel@mayo.edu](mailto:Giblon.rachel@mayo.edu))

Emma Behnken, BA<sub>1</sub> ([Behnken.emma@mayo.edu](mailto:Behnken.emma@mayo.edu))

Paige Organick, BA<sub>1</sub> ([Organick.paige@mayo.edu](mailto:Organick.paige@mayo.edu))

Summer V. Allen, MD<sub>1,4</sub> ([Allen.summer@mayo.edu](mailto:Allen.summer@mayo.edu))

Kevin Shaw, BA<sub>1</sub> ([Shaw.kevin@mayo.edu](mailto:Shaw.kevin@mayo.edu))

Victor M. Montori, MD, MSc<sub>1</sub> ([Montori.victor@mayo.edu](mailto:Montori.victor@mayo.edu))

1. Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota, USA
2. Evidence-Based Practice Center, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA
3. Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA
4. Department of Family Medicine, Mayo Clinic, Rochester, Minnesota

### Corresponding Author:

Kasey R. Boehmer, PhD, MPH  
Mayo Clinic  
200 First Street SW  
Rochester, MN 55905

**Support:** Funded by an internal Mayo Clinic Award from the Robert & Arlene Kogod Center for Aging; This publication was supported by CTSA Grant Number UL1 TR002377 from the National Center for Advancing Translational Science (NCATS). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

**Prior Presentations:** International Shared Decision Making Conference, Lyon, France, 2017; International Conference on Communication in Healthcare, Baltimore, MD, USA, 2017; North American Primary Care Research Group Conference, Montreal, Canada, 2017

**Word Count:** 3,532; 2 Figures, 4 Tables, 1 Appendix

## Abstract

**Purpose:** To pilot test the impact of the ICAN Discussion Aid on clinical encounters.

**Methods:** A pre-post study involving 11 clinicians and 100 patients was conducted at two primary care clinics within a single health system in the Midwest. The study examined clinicians' perceptions about ICAN feasibility, patients' and clinicians' perceptions about encounter success, videographic differences in encounter topics, and medication adherence 6-months after an ICAN encounter.

**Results:** 39/40 control encounters and 45/60 ICAN encounters yielded usable data. Clinicians reported ICAN use was feasible. In ICAN encounters, patients discussed diet, being active, and taking medications more. Clinicians scored themselves poorer regarding visit success than their patients scored them; this effect was more pronounced in ICAN encounters. ICAN did not improve 6-month medication adherence or lengthen visits.

**Conclusion:** This pilot study suggests that using ICAN in primary care is feasible, efficient, and capable of modifying conversations. With lessons learned in this pilot, we are conducting a randomized trial of ICAN vs. usual care in diverse clinical settings.

**Abstract Word Count:** 166

**Keywords:** patient-centered care; minimally disruptive medicine; healthcare communication; chronic disease; multimorbidity

**Trial Registration:** NCT02390570; registered 2/19/2015

### Article Summary: Strengths and limitations of this study

- Small before-after pilot study limiting the ability to draw statistical inferences that would be possible in a larger trial with a randomized design.
- Not powered to assess clinical significance for patient-reported outcomes nor prescription adherence; lack of difference found is not indicative of one not existing
- Single healthcare system in the Midwest with a fairly homogenous patient population limiting generalizability
- Small size was a strength in allowing us to pursue video-recording of all encounters, allowing deeper exploration of ICAN's impact on conversations and additional training needs for future implementation and testing

## 1. Introduction

Estimates in 2013 indicated that 117 million, or approximately half of adults in the U.S. had one or more chronic conditions,<sup>1</sup> while 26% of adults in the U.S. had multiple chronic conditions (MCC).<sup>2</sup> Patients living with chronic conditions must cope with the burden of illness and additionally invest time and energy to comprehend, manage, and access professional healthcare – the work of being a patient. If this work is not carefully managed and monitored, patients may experience treatment burden.<sup>3,4</sup>

Treatment burden often goes unnoticed, as clinical practice guidelines focus on managing individual conditions, without explicit consideration of co-morbidities or the patient's values, preferences, and context.<sup>5</sup> If implemented in this way, the application of all guideline recommendations may overwhelm patients<sup>6-8</sup>. Similarly, clinical practice does not often acknowledge patients' potentially limited capacity to handle complexity of life and healthcare work, which leads to the prescription of treatment plans that require capacity of patients and their caregivers that they may not have.<sup>9,10</sup>

This situation not only impacts patients and families, but has also led to burnt-out clinicians.<sup>11</sup> Beyond medical complexity described above, clinicians also need to consider non-medical complexity, (e.g., difficulty affording medications, unstable housing, and problematic family dynamics), and the body of literature is growing to show that clinicians have difficulty with conversations where medical and non-medical complexity intersect.<sup>12-16</sup>

The ICAN Discussion Aid (**Figure 1**) was developed to address these problems, with the aim of enabling the discussion of patient workload, capacity, and treatment burden within the time constraints of busy primary care visits.<sup>17</sup> The process to develop ICAN is described in full elsewhere.<sup>17</sup> Briefly, it was developed using a robust, iterative user-centered design process,

1  
2  
3 previously used to develop decision aids<sup>18</sup> and was grounded in the Cumulative Complexity  
4  
5 Model, which states that patients living with chronic illness must enact both patient and life work  
6  
7 with limited capacity.<sup>19</sup> When workload exceeds patient capacity, it affects patients' abilities to  
8  
9 access and use healthcare and enact self-care, in turn effecting their health outcomes.<sup>19</sup> In  
10  
11 addition to worsening health outcomes, unaddressed workload-capacity imbalance can lead to a  
12  
13 vicious cycle of added treatment burden and illness burden.<sup>19</sup>  
14  
15  
16  
17

18 To date, the ICAN Discussion Aid remains untested in terms of its impact on the  
19  
20 discussion of patient workload, capacity, and treatment burden in the clinical encounter. We  
21  
22 hypothesize that if ICAN proves feasible in busy primary care and positively impacts the clinical  
23  
24 encounter with greater discussion of patients' context, it could spark treatment plans that better  
25  
26 fit patients' lives, with downstream impact on patient health outcomes and quality of life.  
27  
28  
29

### 30 *1.2. Aim*

31  
32  
33 We aimed to evaluate the feasibility of using the ICAN Discussion Aid in primary care  
34  
35 and to estimate its impact on clinical care, including patient and clinician-perceived success of  
36  
37 visits, length of visits, and topics of conversation.  
38  
39  
40

## 41 **2. Methods**

42  
43  
44 To pilot test the ICAN Discussion Aid, we conducted a pre-test versus post-test  
45  
46 intervention study.  
47  
48

### 49 *2.1. Ethics*

50  
51  
52 All study procedures were approved by the Mayo Clinic IRB (14-008621); patient and  
53  
54 clinician participants consented for data collection procedures.  
55  
56  
57  
58  
59  
60

## 2.2. Participant Eligibility and Recruitment

Clinicians were recruited from two clinical sites in the Midwest and were eligible for participation if they regularly saw patients with chronic conditions. Clinicians were consented for participation either at a lunch-hour clinical practice meeting or immediately before their first eligible patient. Clinicians were consented by the principal investigator (KRB) or a trained study coordinator. Adult patients were eligible if they had one or more chronic conditions, no major barriers to consent (e.g. cognitive impairment), and were seeing a clinician who had agreed to participate. To assess for barriers to consent, we used the electronic medical record to look for keywords such as language, cognitive function, serious vision/hearing impairment, etc., and also confirmed with the primary care clinician that the patients did not have any of the listed barriers to consent and were appropriate to include in the study. Patients were approached immediately before the encounter with their clinician by a trained study coordinator.

## 2.3 Study Procedures

After both clinician and patient were enrolled in the study, a trained study coordinator set up a small video camera (i.e., FlipCam, GoPro) to record the clinic visit. Patients and clinicians could turn the video camera off at any time if they felt uncomfortable, and the video camera was always turned around or off during physical exams. Following the encounter, both patient and clinician were given a survey to complete immediately or return in a postage-paid return envelope. The study coordinator followed-up on surveys not returned within one week. The first 40 clinical encounters were usual care. After the first 40 encounters, clinicians were then trained during a standing meeting or individually on how to use the ICAN Discussion Aid. The remaining 60 clinical encounters were intended to be ICAN encounters.

#### 2.4. Intervention: The ICAN Discussion Aid

The study coordinator provided instructions for the patient to complete the ICAN Discussion Aid (**Figure 1**) before the clinician entered the room. When the clinician entered the room, he or she would select one of three opening questions to elicit responses from the patient, and would then explore the information that the patient provided in ICAN by asking “What stands out to you on this sheet you filled?” Clinicians were instructed to discuss that issue alone and connect it to the reason for the visit that day. Clinical conversation was expected to proceed as usual with incorporation of the ICAN information.

#### 2.5. Measures

Clinician degree, position, and gender were collected at baseline. Patient characteristics of age, sex and marital status were abstracted from the medical record. To assess *perceived success* of the encounter, we used the Consultation Care Measure (CCM), a valid and discriminating tool to measure communication and partnership within a single encounter, previously correlated with patient satisfaction, enablement, and reduced symptom burden.<sup>20</sup> The measure asks patients to what extent they agree with statements about the doctor such as he/she “was interested in what I thought the problem was.”<sup>20</sup> For clinician surveys, we used a modified version of the patient CCM, adjusted to the clinician perspective, which was not previously validated. For example, the patient might be asked the extent to which they felt the clinician “was careful to explain the plan of treatment.” Whereas the clinician would be asked the extent to which they agreed with the statement that they felt that they “were careful to explain the plan of treatment.” To assess *feasibility* of ICAN use, we asked clinicians to report how easy or difficult the aid was to use in their encounter on a 5-point scale, from very easy to very difficult. If clinicians marked difficult or very difficult, they were prompted to write a brief description of

1  
2  
3 why. To assess *adherence*, patients pharmaceutical records were collected as a means to provide  
4 estimates of baseline adherence amongst patients in this population, and of whether using ICAN  
5 potentially effects adherence through the tailoring of patient care plans to their life context.  
6  
7

8  
9  
10 Given the hypothesis generating nature of the adherence data, the methods and results are  
11 provided in **Appendix 1**.  
12  
13

## 14 15 2.6. Videographic Coding Scheme

16  
17  
18 To assess ICAN's *impact on clinical conversation topics*, we created an a priori video  
19 coding scheme, in which we coded each instance where the following topics were brought up:  
20 family, friends, free time, faith, living situation, being active, rest, comfort, emotional life,  
21 senses, memory, eating well, taking medications, making appointments, getting to appointments,  
22 administrative treatment work (e.g., dealing with insurance/billing, communicating with  
23 pharmacies), prescribed behaviors (e.g. getting mammograms, exercising a certain number of  
24 minutes per week), and other treatment work (i.e, work that the patient was asked to do but that  
25 did not fit into these other categories). Life issues listed in the coding scheme were those shown  
26 on ICAN and previously illustrated as important components of patient capacity from earlier  
27 work.<sup>17,21</sup> Treatment burden issues listed in the coding scheme were derived from typical issues  
28 listed in the development of ICAN and a taxonomy of treatment burden.<sup>17,22</sup> We also coded for  
29 opening questions typically used in ICAN, designed to elicit the existence of competing priorities  
30 that could potentially limit the capacity for self-care or treatment, sources of joy in patients'  
31 lives, and immediate concerns (medical and non-medical). To assess *impact on length of visit*,  
32 we compared lengths of video recording.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

## 54 2.7. Analyses

55  
56  
57  
58  
59  
60

All statistical analyses were conducted in SAS (SAS Institute Inc., Version 9.4, Cary, NC, USA) and Stata (StataCorp, Release 15, College Station, TX). Videographic coding was done using Noldus Observer XT (version 11, Leesburg, VA). Patient and clinical encounter characteristics were compared between ICAN and control encounters using a t-test for continuous variables and a chi-square test for categorical variables. To explore differences in patient and clinician perceived success of an encounter, we subtracted unadjusted clinician scores from unadjusted patient scores, and tested for changes in the perceived success gap between ICAN and control encounters using a Wilcoxon Rank-Sum test. To test for differences across issues discussed in videos where patients and clinicians used ICAN versus those recorded in control encounters, we used a negative binomial model accounting for clustering within clinicians.

### *2.8 Patient and Public Involvement*

The Knowledge and Evaluation Research Unit Patient Advisory Group participated in the design of the ICAN Discussion Aid, ensuring its relevance to patients living with chronic conditions and its ease of use. They were not consulted for the research design of the pilot study.

## **3. Results**

Eleven clinicians were enrolled from two primary care clinics within the Midwest, United States starting in October 2015. Seven clinicians approached declined enrollment, without providing a reason. The clinicians were primarily female (N=7, 64%) and were primarily physicians, with one nurse practitioner and two physician assistants. Patient enrollment began October 2015 and ended February 2017. 100 patients consented to participate (ICAN n=60). Detailed enrollment information is depicted in **Figure 2**. Of the eleven clinicians participating,



1  
2  
3 one had all control encounters and five had all ICAN encounters. Patient characteristics are  
4 depicted in **Table 1**. Encounter length did not significantly differ between ICAN and control  
5 encounters.  
6  
7  
8  
9

### 10 11 *3.1. Clinician reported feasibility of ICAN*

12  
13 Clinicians found the tool feasible to use in the majority of encounters. 62% reported it  
14 very easy or easy, 32% reported it as neither easy nor difficult, and 5% reported it was difficult  
15 to use in that encounter. There were two encounters where it was reported as difficult by  
16 different clinicians. For one encounter the clinician stated, "Unfortunately, this made her  
17 appointment go over by about 30 minutes. It was good we discussed issues with the portal [*an*  
18 *online platform that allows patients to access their health information*] and her life and stressors  
19 but it wasn't a big concern (why it wasn't a reason for the appointment) but we spent a good deal  
20 of time on it." Upon further review of this video, it appears that the primary reason that the  
21 encounter lasted substantially longer than planned was a lack of fidelity to ICAN training. After  
22 the clinician asked the patient what stood out to her from ICAN, she continued to elicit  
23 information about each burden listed by the patient, rather than connect the patient's response to  
24 the remainder of the clinical visit. Addressing the two key issues the patient brought up, work  
25 stress and being active, took approximately five and a half minutes in total. Following that, the  
26 clinician spent an additional five and a half minutes reviewing the other items on the tool.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 In the second encounter, the clinician stated, "I enjoy the learning and conversation  
46 obtained from form [*sic*] but didn't have the extra time in schedule [*sic*] necessary to address  
47 each issue - easily added another 15-20 minutes to appointment." In this encounter, the patient  
48 indicated that her emotional life was both a source of satisfaction and a burden. The clinician  
49 enquired further and thus provided the patient with an opportunity to talk about her prolonged  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 grief after the loss of her spouse and her concerns about possible depression. In response the  
4  
5 clinician screened the patient for potential depression. Total time using the tool and discussing  
6  
7 that issue took four minutes of the total visit. The patient was scheduled for a 45 minute general  
8  
9 medical exam, and the total video recorded visit time was 26 minutes, which did not include the  
10  
11 physical exam at the end of the encounter.  
12  
13

### 14 15 16 *3.2. Survey Results*

17  
18  
19 We did not find any items with significant differences between patients in either cohort  
20  
21 for the consultation care measure (**Table 2**). When comparing patients and clinicians across the  
22  
23 consultation care measure, among the items that overlapped, clinicians tended to score  
24  
25 themselves poorer than patients. This was more prevalent when the ICAN tool was used (**Table**  
26  
27 **3**).  
28  
29

### 30 31 32 *3.3. Videographic Results*

33  
34  
35 Issues discussed during clinical encounters did significantly differ between ICAN and  
36  
37 control encounters in multiple domains (**Table 4**). Specifically, discussions about being active,  
38  
39 diet, and taking medications were discussed significantly more frequently in ICAN encounters.  
40  
41 Discussions about administrative treatment work, other treatment work, family, living  
42  
43 arrangements, and comfort were discussed significantly less frequently in ICAN encounters. We  
44  
45 noticed that often topics about family were used as conversation fillers in control encounters,  
46  
47 whereas there may have been less room for this when patients were prompted to bring up issues  
48  
49 that mattered most to them.  
50  
51

## 52 53 54 **4. Discussion and Conclusion**

#### 4.1. Summary of Findings

Within this pilot trial, clinicians found the ICAN Discussion Aid to be a tool they could feasibly adopt into everyday practice and which did not impact the length of the visit. Patients discussed diet, being active, and taking medications more often in ICAN encounters.

Additionally, clinicians elicited competing priorities using ICAN opening questions that were never elicited during the opening of control encounters. While clinicians rated the perceived success of their encounters poorer than their patients (CCM score), and the gap between patient and clinician perceived success was larger ICAN encounters, the difference was not significant. No difference was seen for adherence to prescription medications.

#### 4.2. Limitations and Strengths

These findings cannot be interpreted without considering the limitations in this study design. First, this study was a small before-after pilot study which limits our ability to draw statistical inferences that would be possible in a larger trial with a randomized design. The study was not powered to assess clinical significance for patient-reported outcomes nor prescription adherence and a lack of difference found is not indicative of one not existing. Furthermore, the study occurred within a single healthcare system in the Midwest with a fairly homogenous patient population of mostly high or middle socioeconomic status, which limits the generalizability of the specific changes in topics present in ICAN conversations versus usual care conversations. However, the small size of the study allowed us to pursue video-recording of all encounters, which allowed for deeper exploration of ICAN's impact on conversations and to point to additional needs for future implementation and testing of ICAN in practice that would have been more difficult in a larger multi-site study.

### 4.3 Missing Data

Detailed missing data information is depicted in **Figure 2** and should be considered when interpreting the study's findings. 39/40 baseline encounters yielded usable data. One survey was unreturned and one encounter's videographic coding was lost due to technical error. 45/60 follow-up encounters yielded usable data. 15 videos during the intervention period were excluded from analyses because although the clinician had been trained in using ICAN and intended to use it in the encounter, they did not use the tool during the encounter. This occurred for a variety of reasons including that the patient brought up more pressing concerns for that day that made the clinician feel the ICAN tool was no longer appropriate for that encounter or the clinician simply forgot to use the tool. Consent to pharmacy record review was an optional portion of the study, therefore reducing the number of profiles available. For all patients that consented to this optional portion, pharmacy records were requested. However, in some cases, the pharmacy did not return a profile for the patient after two request attempts, whereas in other cases, the patient did not have any active prescriptions at the pharmacy on file for chronic conditions.

### 4.4. Practice Implications

Feasibility of ICAN use is an important finding on its own, given previously reported challenges by clinicians in providing patient-centered care and participating in shared decision making for populations living with MCC.<sup>23</sup> Furthermore, the difference in the topics brought up in ICAN encounters suggests that patients are indeed more likely to be able to voice their topics of choice, in an area where poor communication has been a noted frustration amongst patients.<sup>24</sup> Diet, being active, and taking medications are not surprising topics to be most important to

1  
2  
3 patients in this setting and population (suburban, Midwest, academic medical center). However,  
4  
5 these topics have been noted as important treatment burden factors for patients in other diverse  
6  
7 samples; patients noted that they were aware their clinicians wanted them to eat healthier or  
8  
9 exercise more frequently, but important barriers existed of which their clinicians were unaware.<sup>25</sup>  
10  
11 Furthermore, in a previous study of patient-clinician concordance, patients were more likely than  
12  
13 clinicians to rank being active as one of their top three health concerns.<sup>26</sup> Future research should  
14  
15 examine whether the topics discussed more often are different in other clinical settings (e.g. rural  
16  
17 and urban), with different populations (e.g. unsalaried clinicians, underserved patients), and what  
18  
19 clinicians can do in clinical encounters with this information.  
20  
21  
22

23  
24  
25 Ultimately, the discussion of topics of greater importance to patients and their competing  
26  
27 priorities is important as it could lead to better tailoring of treatment plans to patients' context,  
28  
29 improving patients' workload-capacity balance in managing chronic illness. As mentioned  
30  
31 earlier, the Cumulative Complexity Model postulates that workload-capacity balance impacts  
32  
33 patients' abilities to access and use healthcare and enact self-care, with downstream impact on  
34  
35 their health outcomes.<sup>19</sup> Furthermore, communication models, such as the one proposed by Street  
36  
37 et al. have postulated the pathways from patient-clinician communication to patient outcomes.<sup>27</sup>  
38  
39 For example, Street's model illustrates that communication functions supported by ICAN such as  
40  
41 managing uncertainty, fostering relationships, and enabling self-management can impact  
42  
43 proximal outcomes such as patient trust and "feeling known," with downstream consequences on  
44  
45 self-care skills, adherence, and ultimately health outcomes.<sup>27</sup> ICAN is a general discussion aid  
46  
47 for use in chronic illness, intended to provide insight into the personal, social, material, and  
48  
49 spiritual aspects of the patient's situation; it can be used in conjunction with the many available  
50  
51 decision-specific conversation aids.<sup>28</sup> For example, an ICAN conversation may illuminate that a  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 patient finds their overall medication regimen particularly burdensome, and this may spark a  
4 treatment-specific conversation about choosing a different treatment in replacement of a current  
5 one or inform the decision to add or not add another medication to the list. A good example of  
6 the use of ICAN and a treatment decision aid is available on the web.<sup>29</sup> Used in this way,  
7  
8 clinicians may fully understand patients' competing priorities as well as treatment-specific  
9 values and preferences, and therefore, be able to co-create with them treatment plans that fit their  
10 context and allow them to lead quality lives to the fullest extent.  
11  
12  
13  
14  
15  
16  
17  
18  
19

20  
21 Examining the two encounters noted as difficult for clinicians yielded important  
22 information about ICAN implementation challenges. The encounter where additional time was  
23 used to discuss all ICAN items suggests that additional training may be needed for clinicians to  
24 illustrate how to connect the initial question of "What stands out to you?" to the clinical reason  
25 for the appointment, and how to continue the use of the discussion aid at future encounters. In  
26 the encounter in which the patient was able to discuss potential concerns of depression, the  
27 clinician noted that this added an additional 15 – 20 minutes to the encounter, whereas the actual  
28 discussion took less than five minutes. The perceived duration may have felt longer than the  
29 actual duration because of the heavy nature of the topic discussed. Past research in primary care  
30 patients with multi-morbidity has shown that clinician comfort level with these types of difficult  
31 topics is low and that in practicing a traditional "additive-sequential model," where each problem  
32 is treated independently and prioritized, these issues may never get acknowledged.<sup>15,30</sup> Therefore,  
33 the implementation of ICAN can provide an opportunity to train clinicians to address potentially  
34 difficult topics, manage their expectations of those discussions, and learn how to successfully  
35 have those conversations. Specifically, this requires attention and clinician exposure in future  
36 ICAN trainings to the potentially uncomfortable and off-script conversations that may occur as a  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 result of using the aid, as well as practice in having those conversations first in safe spaces, such  
4  
5 as with peers and trainers, prior to real-life clinical encounters.  
6  
7

#### 8 9 *4.5. Conclusion*

10  
11 In conclusion, we successfully pilot tested the ICAN Discussion Aid in primary care  
12  
13 encounters. This study illustrated that ICAN was perceived as feasible to implement in normal  
14  
15 clinical practice, did not impact visit length, and impacted the conversation topics discussed in  
16  
17 encounters. While patients perceived improved visit success with ICAN use, clinicians perceived  
18  
19 worsened visit success. Clinical encounters that were noted as difficult to use ICAN point to  
20  
21 additional ICAN training needs in future implementation and study settings. ICAN deserves  
22  
23 further testing to determine if its implementation leads to better workload-capacity balance for  
24  
25 patients living with chronic illness and if this translates to improved patient health outcomes.  
26  
27  
28  
29

#### 30 31 *Authors' contributions*

32  
33  
34 KRB was responsible for study design, overall study execution, analysis, and the draft  
35  
36 manuscript. CCD and AT conducted videographic analysis and provided critical revisions for the  
37  
38 manuscript. MB and RG conducted statistical analysis, created tables, and drafted the statistical  
39  
40 sections of the manuscript. EB was responsible for study coordination of the study and data  
41  
42 collection procedures. PO assisted with data cleaning procedures, drafting of the manuscript, and  
43  
44 critical revisions to the manuscript. SVA served as clinical champion for the study and provided  
45  
46 critical revisions to the manuscript. KS provided revisions to the manuscript and data  
47  
48 visualization. VMM assisted KRB with study design and oversight of the project.  
49  
50  
51

#### 52 53 *Conflicts of Interests*

54  
55  
56  
57  
58  
59  
60

1  
2  
3 The authors of this manuscript have no conflicts of interests to report.  
4  
5

6 *Funding Statement*  
7

8  
9 This research was supported in part by an internal award from the Mayo Clinic Robert and  
10  
11 Arlene Kogod Center for Aging.  
12  
13

14  
15 *Data Availability*  
16

17  
18 Patients in this study provided informed consent regarding the use of their de-identified data  
19  
20 beyond the proposed study. De-identified data from participants that consented to future use of  
21  
22 their data is available upon request from investigators in the Knowledge and Evaluation  
23  
24 Research Unit.  
25  
26

27  
28 *Included Figures*  
29

30  
31 Figure 1: ICAN Discussion Aid  
32  
33

34  
35 Figure 2: Detailed Enrollment Information  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## References

1. Centers for Disease Control. Chronic Diseases: The Leading Causes of Death and Disability in the United States. <https://www.cdc.gov/chronicdisease/overview/>. Published 2017. Accessed May 17, 2018.
2. Ward BW, Schiller JS. Prevalence of multiple chronic conditions among US adults: estimates from the National Health Interview Survey, 2010. *Prev Chronic Dis*. 2013;10:E65.
3. Eton DT, Ramalho de Oliveira D, Egginton JS, et al. Building a measurement framework of burden of treatment in complex patients with chronic conditions: a qualitative study. *Patient related outcome measures*. 2012;3:39-49.
4. Ridgeway JL. Factors that lessen the burden of treatment in complex patients with chronic conditions: A qualitative study. In:2013.
5. Wyatt KD, Stuart LM, Brito JP, et al. Out of context: clinical practice guidelines and patients with multiple chronic conditions: a systematic review. *Med Care*. 2014;52 Suppl 3:S92-S100.
6. Gallacher K, May CR, Montori VM, Mair FS. Understanding patients' experiences of treatment burden in chronic heart failure using normalization process theory. *Annals of family medicine*. 2011;9(3):235-243.
7. Gallacher K, Morrison D, Jani B, et al. Uncovering treatment burden as a key concept for stroke care: a systematic review of qualitative research. *PLoS medicine*. 2013;10(6):e1001473.
8. Shippee ND, Shippee TP, Hess EP, Beebe TJ. An observational study of emergency department utilization among enrollees of Minnesota Health Care Programs: financial and non-financial barriers have different associations. *BMC health services research*. 2014;14:62.
9. May C, Montori VM, Mair FS. We need minimally disruptive medicine. *BMJ*. 2009;339:b2803.
10. May CR, Eton DT, Boehmer K, et al. Rethinking the patient: using Burden of Treatment Theory to understand the changing dynamics of illness. *BMC health services research*. 2014;14:281.
11. Bodenheimer T, Chen E, Bennett HD. Confronting the growing burden of chronic disease: can the U.S. health care workforce do the job? *Health affairs*. 2009;28(1):64-74.
12. Bayliss EA, Ellis JL, Steiner JF. Seniors' self-reported multimorbidity captured biopsychosocial factors not incorporated into two other data-based morbidity measures. *Journal of clinical epidemiology*. 2009;62(5):550-557 e551.
13. Cottrell E, Yardley S. Lived experiences of multimorbidity: An interpretative meta-synthesis of patients', general practitioners' and trainees' perceptions. *Chronic illness*. 2015;11(4):279-303.
14. Loeb DF, Binswanger IA, Candrian C, Bayliss EA. Primary care physician insights into a typology of the complex patient in primary care. *Annals of family medicine*. 2015;13(5):451-455.
15. O'Brien R, Wyke S, Guthrie B, Watt G, Mercer S. An 'endless struggle': a qualitative study of general practitioners' and practice nurses' experiences of managing multimorbidity in socio-economically deprived areas of Scotland. *Chronic illness*. 2011;7(1):45-59.
16. Safford MM. The Complexity of Complex Patients. *Journal of general internal medicine*. 2015;30(12):1724-1725.
17. Boehmer KR, Hargraves IG, Allen SV, Matthews MR, Maher C, Montori VM. Meaningful Conversations in Living with and Treating Chronic Conditions: Development of the ICAN Discussion Aid. *BMC health services research*. 2016.

18. Breslin M, Mullan RJ, Montori VM. The design of a decision aid about diabetes medications for use during the consultation with patients with type 2 diabetes. *Patient education and counseling*. 2008;73(3):465-472.
19. Shippee ND, Shah ND, May CR, Mair FS, Montori VM. Cumulative complexity: a functional, patient-centered model of patient complexity can improve research and practice. *Journal of clinical epidemiology*. 2012;65(10):1041-1051.
20. Little P, Everitt H, Williamson I, et al. Observational study of effect of patient centredness and positive approach on outcomes of general practice consultations. *BMJ*. 2001;323(7318):908-911.
21. Boehmer KR, Gionfriddo MR, Rodriguez-Gutierrez R, et al. Patient capacity and constraints in the experience of chronic disease: a qualitative systematic review and thematic synthesis. *BMC family practice*. 2016;17(1):127.
22. Tran VT, Barnes C, Montori VM, Falissard B, Ravaud P. Taxonomy of the burden of treatment: a multi-country web-based qualitative study of patients with chronic conditions. *BMC medicine*. 2015;13:115.
23. Academy of Medical Sciences. Multimorbidity: A priority for global health research. <https://acmedsci.ac.uk/policy/policy-projects/multimorbidity>. Published 2018. Accessed June 6, 2018.
24. Gill A, Kuluski K, Jaakkimainen L, Naganathan G, Upshur R, Wodchis WP. "Where do we go from here?" Health system frustrations expressed by patients with multimorbidity, their caregivers and family physicians. *Healthc Policy*. 2014;9(4):73-89.
25. Eton DT, Ridgeway JL, Egginton JS, et al. Finalizing a measurement framework for the burden of treatment in complex patients with chronic conditions. *Patient Relat Outcome Meas*. 2015;6:117-126.
26. Zulman DM, Kerr EA, Hofer TP, Heisler M, Zikmund-Fisher BJ. Patient-provider concordance in the prioritization of health conditions among hypertensive diabetes patients. *J Gen Intern Med*. 2010;25(5):408-414.
27. Street RL, Jr., Makoul G, Arora NK, Epstein RM. How does communication heal? Pathways linking clinician-patient communication to health outcomes. *Patient education and counseling*. 2009;74(3):295-301.
28. Stacey D, Legare F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. *Cochrane Database Syst Rev*. 2017;4:CD001431.
29. Mayo Clinic. My Life, My Healthcare (ICAN) and Statin Choice used in a single visit. <https://www.youtube.com/watch?v=a0H9RRGIFJg>. Published 2017. Accessed May 8, 2019.
30. Bower P, Macdonald W, Harkness E, et al. Multimorbidity, service organization and clinical decision making in primary care: a qualitative study. *Fam Pract*. 2011;28(5):579-587.

	ICAN (N=57*)	Pre-Intervention (N=40)	Total (N=97)	p value
<b>Sex</b>				0.09
Female	40 (70.2%)	34 (85.0%)	74 (76.3%)	
<b>Age: Mean (SD)</b>	62.7 (12.0)	66.8 (15.0)	64.4 (13.4)	0.05
<b>Marital status</b>				0.37
Divorced	11 (19.3%)	3 (7.5%)	14 (14.4%)	
Married	36 (63.2%)	27 (67.5%)	63 (64.9%)	
Single	5 (8.8%)	4 (10.0%)	9 (9.3%)	
Widowed	5 (8.8%)	6 (15.0%)	11 (11.3%)	
<b>Length of encounter (minutes): Mean (SD)</b>	31.6 (13.4)	34.5 (11.7)	32.9 (12.7)	0.25
Median (Q1, Q3)	31.3 (19, 41)	34.3 (25, 44)	33.6 (22, 42)	

<sup>^</sup>All enrolled patients.

\*3 patients in intervention missing data on characteristics.

**Table 2: CCM Patient Scores**

	ICAN (N=42)	Pre-Intervention (N=39)	Total (N=81)
<b>Overall score</b>			
Mean (SD)	29.7 (11.0)	28.6 (12.4)	29.2(11.6)
Median (Range)	25 (21, 62)	23 (21, 74)	24 (21, 74)
Adjusted mean* (95% CI)	31.5 (24.6, 38.5)	34.6 (29.3, 42.9)	

\*Adjusted by clinician clustering; lower scores = better

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 3: Clinician – Patient Difference in individual CCM scores**

	ICAN (N=38)*	Pre-Intervention (n=39)*	P-Value
1/E: Careful to explain	0.87 (0.52, 1.22)	0.64 (0.32, 0.96)	0.33
2/F: Was sympathetic	0.97 (0.57, 1.37)	0.54 (0.19, 0.89)	0.09
3/H: discussed & agreed together what problem was	0.97 (0.61, 1.33)	0.51 (0.19, 0.84)	0.047
4/K: discussed & agreed on plan of treatment	0.84 (0.51, 1.17)	0.59 (0.25, 0.93)	0.26
5/M: understood emotional needs	0.97 (0.43, 1.52)	0.77 (0.39, 1.15)	0.31
6/N: confident knows patient history	0.66 (0.23, 1.09)	0.77 (0.40, 1.14)	0.91
7/T: interested in effect of problem on family and personal life	0.68 (0.22, 1.15)	0.64 (0.27, 1.02)	0.73
8/U: interested in effect of problem on everyday life	0.82 (0.35, 1.29)	0.74 (0.39, 1.10)	0.60

Mean (95% CI), p-value Wilcoxon rank sum test

\* Difference in scores calculated as clinician score minus patient score for encounter. Higher scores correspond to lower performance on the CCM tool.

**Table 4: Videographic Analysis of Issues Discussed by Patients and Clinicians**

	Behaviors *	All Encounters (n=84/ICAN= 45)		Patients (n=84)		Clinicians (n=84)	
		IRR (95% CI)	P value	IRR (95% CI)	P value	IRR (95% CI)	P value
<b>More likely with ICAN</b>	<b>Being active</b>	<b>1.52 (1.09, 2.11)</b>	<b>0.01</b>	<b>1.58 (1.12, 2.22)</b>	<b>0.008</b>	1.45 (0.95, 2.21)	0.09
	<b>Taking medications</b>	1.22 (0.99, 1.51)	0.06	<b>1.42 (1.20, 1.67)</b>	<b>&lt;.0001</b>	1.12 (0.85, 1.46)	0.42
	<b>Diet</b>	<b>2.02 (1.22, 3.32)</b>	<b>0.005</b>	<b>2.32 (1.39, 3.88)</b>	<b>0.001</b>	1.61 (0.93, 2.79)	0.09
	<b>Competing priorities</b>	<b>14.46 (4.00, 52.24)</b>	<b>&lt;.0001</b>	---**	---	<b>10.91 (3.63, 32.73)</b>	<b>&lt;.0001</b>
<b>Less Likely with ICAN</b>	<b>Other admin</b>	<b>0.56 (0.39, 0.82)</b>	<b>0.002</b>	0.74 (0.48, 1.13)	0.16	<b>0.47 (0.33, 0.69)</b>	<b>&lt;.0001</b>
	<b>Family</b>	<b>0.57 (0.36, 0.90)</b>	<b>0.02</b>	0.66 (0.42, 1.03)	0.05	<b>0.46 (0.28, 0.75)</b>	<b>0.002</b>
	<b>Faith</b>	<b>0.59 (0.42, 0.82)</b>	<b>0.002</b>	0.78 (0.44, 1.39)	0.41	0.36 (0.12, 1.05)	0.06
	<b>Senses</b>	<b>0.55 (0.30, 1.00)</b>	<b>0.05</b>	0.65 (0.35, 1.22)	0.18	<b>0.44 (0.23, 0.87)</b>	<b>0.02</b>
<b>No Difference with ICAN</b>	Other treatment work	0.90 (0.65, 1.24)	0.52	1.07 (0.71, 1.63)	0.74	0.77 (0.59, 1.01)	0.06
	Immediate concerns	1.11 (0.69, 1.76)	0.68	1.62 (0.86, 3.06)	0.14	0.90 (0.60, 1.37)	0.64
	Joy	---**	---	---**	---	---**	---
	Where I live	0.82 (0.50, 1.35)	0.44	1.09 (0.66, 1.80)	0.75	0.58 (0.32, 1.04)	0.07
	Comfort	0.76 (0.50, 1.16)	0.20	0.90 (0.62, 1.33)	0.61	0.63 (0.39, 1.01)	0.05
	Free time	1.08 (0.54, 2.16)	0.82	1.20 (0.60, 2.40)	0.61	0.96 (0.45, 2.04)	0.92
	Making appointments	0.76 (0.50, 1.16)	0.21	0.77 (0.49, 1.23)	0.27	0.75 (0.49, 1.15)	0.18
	Prescribed behaviors	0.84 (0.45, 1.58)	0.59	0.96 (0.57, 1.64)	0.89	0.80 (0.40, 1.61)	0.53
	Friends	0.75 (0.33, 1.66)	0.47	0.65 (0.30, 1.40)	0.27	1.41 (0.52, 3.75)	0.49
	Getting to appointments	1.24 (0.74, 2.08)	0.41	1.34 (0.76, 2.36)	0.32	1.09 (0.60, 2.00)	0.78
	Work	0.85 (0.60, 1.220)	0.39	1.05 (0.75, 1.47)	0.80	0.62 (0.38, 1.02)	0.06
	Rest	0.89 (0.52, 1.54)	0.68	0.92 (0.52, 1.59)	0.75	0.87 (0.46, 1.64)	0.67
	Emotional life	1.23 (0.54, 2.80)	0.63	1.56 (0.64, 3.83)	0.33	1.03 (0.41, 2.59)	0.95
	Volunteer	0.85 (0.30, 2.38)	0.76	0.57 (0.16, 2.04)	0.39	---**	---
	Personal meaning	2.39 (0.18, 32.56)	0.51	2.39 (0.18, 31.56)	0.51	---**	---
School	---**	---	---**	---	---**	---	
Memory	1.98 (0.70, 5.63)	0.20	2.41 (0.71, 8.25)	0.1596	0.80 (0.30, 2.13)	0.65	

IRR = Incidence Rate Ratio; >1 means more occurrences in ICAN encounters, <1 fewer occurrences in ICAN encounters  
 \*Adjusted for gender, age at enrollment, length of encounter and clustering around shared clinicians  
 \*\* Insufficient data for analysis

36/bmjopen-2019-029105 on 3 September 2019. Downloaded from <http://bmjopen.bmj.com/> on April 23, 2024 by guest. Protected by copyright.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



- What are you doing when you're not sitting here with me?
- Where do you find the most joy in your life?
- What's on your mind today?

These questions can help shift discussion towards the broader life of your patient. Use as many of them as you wish.

Are these areas of your life a source of satisfaction, burden, or both?

	Satisfaction	Burden
My family and friends	<input type="checkbox"/>	<input type="checkbox"/>
My work	<input type="checkbox"/>	<input type="checkbox"/>
Free time, relaxation, fun	<input type="checkbox"/>	<input type="checkbox"/>
Faith or personal meaning	<input type="checkbox"/>	<input type="checkbox"/>
Where I live	<input type="checkbox"/>	<input type="checkbox"/>
Getting out and transportation	<input type="checkbox"/>	<input type="checkbox"/>
Being active	<input type="checkbox"/>	<input type="checkbox"/>
My rest and comfort	<input type="checkbox"/>	<input type="checkbox"/>
My emotional life	<input type="checkbox"/>	<input type="checkbox"/>
My senses and memory	<input type="checkbox"/>	<input type="checkbox"/>
Eating well	<input type="checkbox"/>	<input type="checkbox"/>


What are the things that your doctors or clinic have asked you to do to care for your health?

Do you feel that they are a help, a burden, or both?

	Help	Burden
<i>example: come in for appointments</i>	<input type="checkbox"/>	<input type="checkbox"/>
<i>example: take aspirin</i>	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>



Figure 1: ICAN Discussion Aid  
419x215mm (300 x 300 DPI)





## Appendix 1: Pharmaceutical prescription methods and results

*Measure*

Patients' prescriptions that had been filled were obtained from their pharmacies directly. We collected information on patients' filled prescriptions six months prior to enrollment to six months post-enrollment. Adherence to treatment was assessed for the six months post-enrollment by calculating the percentage of days out of the 180 day period for which a patient had a filled prescription.[23] Medications to treat chronic conditions were considered for inclusion in analysis.

<b>Appendix Table 1: Included Medications</b>	
<b>Medication Class</b>	<b>Medication Name</b>
<b>ACE inhibitor</b>	<b>Enalapril Maleate</b>
	<b>Lisinopril</b>
	<b>Ramipril</b>
<b>Alpha blocker</b>	<b>Tamsulosin</b>
	<b>Tamsulosin HCL</b>
<b>Alpha1 adrenergic blocker</b>	<b>Doxazosin Mesylate</b>
<b>Alpha2 delta ligand</b>	<b>Lyrica</b>
<b>Aminoketone antidepressant</b>	<b>Bupropion</b>
	<b>Bupropion HCL</b>
	<b>Bupropion HCL ER</b>
	<b>Bupropion XL</b>
	<b>SR Bupropion</b>
<b>Angiotensin receptor blocker (ARB)</b>	<b>Candesartan</b>
	<b>Lorsartan Potassium</b>
	<b>Losartan</b>
	<b>Losartan -HCTZ</b>
	<b>Losartan HCTZ</b>
	<b>Losartan Potassium</b>
	<b>Losartan-HCTZ</b>
	<b>Valsartan</b>
<b>Antiandrogen</b>	<b>Bicalutamide</b>
<b>Antiarrhythmic drug</b>	<b>Amiodarone</b>
	<b>Flecainide Acetate</b>

<b>Appendix Table 1: Included Medications</b>	
<b>Medication Class</b>	<b>Medication Name</b>
<b>Anticoagulant</b>	<b>Enoxaparin Sodium</b>
	<b>Jantoven</b>
	<b>Warfarin Sodium</b>
	<b>Xarelto</b>
<b>Anticonvulsant</b>	<b>Carbamazepine</b>
	<b>Carbamazepine ER</b>
	<b>Gabapentin</b>
	<b>Lamotrigine</b>
	<b>Topiramate</b>
	<b>Zonisamide</b>
<b>Anxiolytic antianxiety agent</b>	<b>Buspirone</b>
<b>Atypical antipsychotic</b>	<b>Latuda</b>
	<b>Quetiapine</b>
	<b>Quetiapine Fumarate</b>
<b>Beta blocker</b>	<b>Atendlol Chlorthalidone</b>
	<b>Atenolol</b>
	<b>Bisoprolol</b>
	<b>Carvedilol</b>
	<b>ER Metoprolol</b>
	<b>Metoprolol ER</b>
	<b>Metoprolol ER Succinate</b>
	<b>Metoprolol SUCC ER</b>
	<b>Metoprolol Tart</b>
	<b>Metoprolol Tartrate</b>
<b>Metoprololhydrochloroth</b>	
<b>Biguanide</b>	<b>Metforman</b>
	<b>Metformin</b>
	<b>Metformin ER</b>
	<b>Metformin HCL</b>

<b>Appendix Table 1: Included Medications</b>	
<b>Medication Class</b>	<b>Medication Name</b>
	<b>Metformin HCL ER</b>
	<b>metformin</b>
<b>Bisphosphonate</b>	<b>Alendronate</b>
	<b>Alendronate Sodium</b>
<b>Calcium channel blocker</b>	<b>Amlodipine</b>
	<b>Amlodipine Besylate</b>
	<b>Diltiazem HCL ER</b>
	<b>Nifedipine</b>
	<b>Verapamil HCR ER</b>
<b>Central alpha agonist</b>	<b>Clonidine HCL</b>
<b>Central muscle relaxant</b>	<b>Methocarbamol</b>
<b>Class 1b antiarrhythmic drug</b>	<b>Lidocaine</b>
<b>DDP4 inhibitor + biguanide</b>	<b>Janumet XR</b>
<b>Dibenzazepine</b>	<b>Tegretol XR</b>
<b>Digitalis glycoside</b>	<b>Digoxin</b>
<b>Disease modifying antirheumatic drug (DMARD)</b>	<b>Hydroxychloroquine Sulfate</b>
<b>Diuretic</b>	<b>Hydrochlorothiazide</b>
	<b>Hydrochlorothiazide</b>
	<b>Metolazone</b>
<b>Fibric acid</b>	<b>Fenofibrate</b>
	<b>Fenofibrate Micronized</b>
<b>Janus kinase (JAK) inhibitors</b>	<b>Xeljanz</b>
<b>Leukotriene receptor antagonists</b>	<b>Montelukast Sodium</b>
<b>Loop diuretic</b>	<b>Furobemide</b>
	<b>Furosemide</b>
	<b>Torsemide</b>
<b>Nitrate</b>	<b>Isosorb Mono ER</b>
	<b>Isosorbide MN ER</b>
<b>Nonergoline dopamine agonist</b>	<b>Pramipexole</b>
<b>Oral diuretic</b>	<b>Triamterene-HCTZ</b>

<b>Appendix Table 1: Included Medications</b>	
<b>Medication Class</b>	<b>Medication Name</b>
<b>P2Y12 inhibitor</b>	<b>Clopidogrel</b>
	<b>Clopidogrel Bisulfate</b>
<b>Phenylpiperazine antidepressant</b>	<b>Nefazodone HCL</b>
<b>Phosphodiesterase 4 (PDE4) inhibitors</b>	<b>Otezla</b>
<b>Potassium sparing diuretic</b>	<b>Spirolactone</b>
<b>SNRI</b>	<b>Desvenlafaxine ER</b>
	<b>Duloxetine DR</b>
	<b>Duloxetine HCL</b>
	<b>Duloxetine Hcl</b>
	<b>ER Venlafaxine</b>
	<b>Escitalopram Oxalate</b>
	<b>Venlafaxine XR</b>
	<b>Venlafaxin XR</b>
	<b>Venlafaxine ER</b>
	<b>Venlafaxine HCL ER</b>
<b>SSRI</b>	<b>Citalopram</b>
	<b>Citalpram</b>
	<b>Fluoxetine</b>
	<b>Fluoxetine HCL</b>
	<b>Paroxetine</b>
	<b>Paroxetine HCL</b>
	<b>Sertraline</b>
	<b>Sertraline HCL</b>
<b>Selective estrogen receptor modulator (SERM)</b>	<b>Raloxifene HCL</b>
	<b>Tamoxifen</b>
<b>Statin</b>	<b>Atorvastatin</b>
	<b>Atorvastatin Calcium</b>
	<b>Locastatin</b>
	<b>Lovastatin</b>

<b>Appendix Table 1: Included Medications</b>	
<b>Medication Class</b>	<b>Medication Name</b>
	<b>Pravastatin Sodium</b>
	<b>Rosuvastatin Calcium</b>
	<b>Simvastatin</b>
	<b>Vytorin</b>
<b>Sulfonylurea</b>	<b>Climepiride</b>
	<b>Glimepiride</b>
	<b>Glipizide</b>
	<b>Glipizide ER</b>
	<b>Glipizide XL</b>
<b>Tetracyclic antidepressant</b>	<b>Mirtazapine</b>
<b>Thiazide diuretic</b>	<b>Chlorthalidone</b>
<b>Thyroxine; T4 (synthetic)</b>	<b>Levothroxine</b>
	<b>Levothyroxine</b>
	<b>Levothyroxine SOD</b>
	<b>Synthroid</b>
<b>Triazolopyridine antidepressant</b>	<b>Trazodone HCL</b>
<b>Tricyclic antidepressant</b>	<b>Amitriptyline HCL</b>
	<b>Cyclobenzaprine HCL</b>
	<b>Cyclovenzaprine HCL</b>
	<b>Cyclovenzaprine HCL</b>
	<b>Nortriptyline</b>
	<b>Nortriptyline</b>
	<b>Nortriptyline HCL</b>
<b>Triiodothyronine</b>	<b>Liothyronine Sodium</b>
<b>Valeric acid</b>	<b>Gemfibrozil</b>
<b>Missing</b>	<b>Missing</b>
<b>Other / Unknown</b>	<b>Amsulosin</b>
	<b>Isometh-apap-dichlor-</b>
	<b>Metromin HCL</b>
	<b>Oxycodone 5MG IR Tabs</b>

### Statistical Analysis

Adherence to medications was assessed by medication class (i.e. if patient had multiple medications within a class, average adherence was calculated). Adherence was modeled using a hierarchical generalized linear model where the outcome was a patients' medication class adherence six months post enrollment. The model was clustered by patient, as patients could have multiple classes of medication, and adjusted by their adherence to the medication class in the six months prior to enrollment and intervention arm. Patients who did not have the medication class in the prior period were set to zero for baseline and a missing indicator was assessed in the model to address this. Patients with missing pharmacy data (e.g. their pharmacy

### Adherence Results

Similar rates of medication counts, medication classes and adherence were seen between groups in the six months prior to the encounter of interest (76% of days covered in patients in the ICAN group vs. 71% control) was unreachable for data request) were not included in the analysis.

<b>Appendix Table 2: Analysis of percent of days covered of medication classes by intervention.</b>			
	ICAN (N=53)	Pre- Intervention (N=27)	p value
<b>Count of medications prior to encounter</b>			0.57
Mean (SD)	3.6 (2.6)	4.2 (3.3)	
Median (IQR)	3 (2, 5)	4 (2, 5)	
<b>Count of medication classes prior to encounter</b>			0.54
Mean (SD)	3.4 (2.3)	3.9 (2.9)	
Median	3 (1, 5)	4 (2, 5)	
<b>Adherence (PDC) prior to encounter</b>			0.94
Mean (95% CI)	55% (50, 60)	54% (50, 60)	
<b>Count of medications post encounter</b>			0.37
Mean (SD)	3.8 (2.5)	4.1 (2.0)	
Median	3 (2, 5)	4 (3, 5)	
<b>Count of medication classes post encounter</b>			0.36
Mean (SD)	3.6 (2.3)	3.9 (1.8)	
Median	3 (2, 5)	4 (3, 5)	

<b>Appendix Table 2: Analysis of percent of days covered of medication classes by intervention.</b>			
	ICAN (N=53)	Pre- Intervention (N=27)	p value
<b>Adherence (PDC) post encounter</b>			0.56
Mean (95% CI)	75% (70, 80)	71% (60, 80)	
<b>Adjusted adherence (PDC) post encounter<sup>^</sup></b>			0.43
Mean (95% CI)	76% (70, 80)	72% (60, 80)	

Acronym: PDC Percent of Days Covered

\* Prior and post encounter periods are each 6 months long.

<sup>^</sup> ANCOVA with random effect of clinician and adjusted by prior 6 months adherence and intervention.